US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US6121424A
(en)
*
|
1991-11-25 |
2000-09-19 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5582996A
(en)
*
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
CA2097060A1
(en)
*
|
1990-12-04 |
1992-06-05 |
Peter J. Curtis |
Bifunctional antibodies and method of preparing same
|
CA2063035A1
(en)
*
|
1991-03-27 |
1992-09-28 |
Klaus Karjalainen |
Chimaeric antibodies containing the ligand domain of cd4
|
AU656181B2
(en)
*
|
1991-05-03 |
1995-01-27 |
Pasteur Sanofi Diagnostics |
Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
|
DE4118120A1
(de)
*
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US7018809B1
(en)
*
|
1991-09-19 |
2006-03-28 |
Genentech, Inc. |
Expression of functional antibody fragments
|
US5932448A
(en)
*
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
EP0654085B1
(en)
*
|
1992-01-23 |
1997-04-02 |
MERCK PATENT GmbH |
Monomeric and dimeric antibody-fragment fusion proteins
|
DE4233152A1
(de)
|
1992-10-02 |
1994-04-07 |
Behringwerke Ag |
Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
|
WO1994012520A1
(en)
*
|
1992-11-20 |
1994-06-09 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
CA2154667A1
(en)
*
|
1993-02-02 |
1994-08-18 |
Linda M. Gustavson |
Directed biodistribution of small molecules
|
WO1995009917A1
(en)
*
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
JPH09507074A
(ja)
*
|
1993-12-23 |
1997-07-15 |
イミュネックス・コーポレーション |
Cd40を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
|
WO1996013583A2
(en)
*
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5656730A
(en)
*
|
1995-04-07 |
1997-08-12 |
Enzon, Inc. |
Stabilized monomeric protein compositions
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
US20050136066A1
(en)
*
|
1996-06-12 |
2005-06-23 |
Yajun Guo |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
EP0981748A4
(en)
*
|
1997-02-26 |
2002-09-18 |
Ban-An Khaw |
IMPROVEMENT OF THE SIGNAL OF A BISPECIFIC POLYMER PROBE FOR IMMUNODAYS
|
US20010024795A1
(en)
*
|
1997-02-26 |
2001-09-27 |
Khaw Ban-An |
Immunoassay technique using multispecific molecules
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
KR100794454B1
(ko)
|
1997-04-07 |
2008-01-16 |
제넨테크, 인크. |
항-vegf 항체
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
IL132560A0
(en)
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
*
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
PT998486E
(pt)
*
|
1997-06-13 |
2007-08-21 |
Genentech Inc |
''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
|
AU8296098A
(en)
*
|
1997-07-08 |
1999-02-08 |
Board Of Regents, The University Of Texas System |
Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
EP2014677A1
(en)
|
1997-11-21 |
2009-01-14 |
Genentech, Inc. |
A-33 related antigens and their pharmacological uses
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
EP2189791A3
(en)
|
1998-02-04 |
2011-03-09 |
Life Technologies Corporation |
Microarrays and uses therefor
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
EP1078060B1
(en)
*
|
1998-05-11 |
2007-01-10 |
E.P. Prof. Dr. Rieber |
Antibodies to dendritic cells and human dendritic cell populations and uses thereof
|
EP2333069A3
(en)
|
1998-05-15 |
2011-09-14 |
Genentech, Inc. |
Therapeutic uses of IL-17 homologous polypeptides
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7387772B1
(en)
*
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US7052872B1
(en)
|
1999-06-22 |
2006-05-30 |
Immunomedics, Inc. |
Bi-specific antibodies for pre-targeting diagnosis and therapy
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
CA2690395C
(en)
|
1998-06-22 |
2013-11-05 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
DK1100830T3
(da)
*
|
1998-07-28 |
2004-01-19 |
Micromet Ag |
Heterominiantistoffer
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
EP1124568B1
(en)
*
|
1998-10-21 |
2007-08-22 |
Altor BioScience Corporation |
Polyspecific binding molecules and uses thereof
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
EP2075335A3
(en)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US7115262B1
(en)
|
1999-03-16 |
2006-10-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric protein for prevention and treatment of HIV infection
|
US6466977B1
(en)
*
|
1999-05-06 |
2002-10-15 |
Cisco Technology, Inc. |
Proxy on demand
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
HU226742B1
(en)
|
1999-06-25 |
2009-08-28 |
Genentech Inc |
Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
|
NZ517150A
(en)
|
1999-08-27 |
2005-01-28 |
Genentech Inc |
Dosages for treatment with anti-ErbB2 antibodies
|
US20040214783A1
(en)
|
2002-05-08 |
2004-10-28 |
Terman David S. |
Compositions and methods for treatment of neoplastic disease
|
US7272649B1
(en)
*
|
1999-09-30 |
2007-09-18 |
Cisco Technology, Inc. |
Automatic hardware failure detection and recovery for distributed max sessions server
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
CA2389317A1
(en)
|
1999-10-20 |
2001-04-26 |
Frederic J. De Sauvage |
Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
|
US6917626B1
(en)
*
|
1999-11-30 |
2005-07-12 |
Cisco Technology, Inc. |
Apparatus and method for automatic cluster network device address assignment
|
CA2490853A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1897945T3
(da)
|
1999-12-23 |
2012-05-07 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
|
US6895434B1
(en)
*
|
2000-01-03 |
2005-05-17 |
Cisco Technology, Inc. |
Sharing of NAS information between PoPs
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
AU2001236485A1
(en)
*
|
2000-01-21 |
2001-07-31 |
Mallinckrodt, Inc. |
Novel orthogonally protected amino acid chelators for biomedical applications
|
US20040052793A1
(en)
*
|
2001-02-22 |
2004-03-18 |
Carter Paul J. |
Caspase activivated prodrugs therapy
|
NZ520458A
(en)
*
|
2000-02-24 |
2005-02-25 |
Genentech Inc |
Caspase activated prodrugs therapy
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
LT2857516T
(lt)
|
2000-04-11 |
2017-09-11 |
Genentech, Inc. |
Multivalentiniai antikūnai ir jų panaudojimas
|
EP1299128A2
(en)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
CA2709771A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
DK2042597T3
(da)
|
2000-06-23 |
2014-08-11 |
Genentech Inc |
Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
US7534429B2
(en)
|
2000-11-29 |
2009-05-19 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD63
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
KR100861466B1
(ko)
|
2001-04-24 |
2008-10-02 |
메르크 파텐트 게엠베하 |
항혈관형성제 및 TNFα를 이용한 병용 요법
|
CA2448956C
(en)
|
2001-05-30 |
2017-10-03 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
US20060270003A1
(en)
|
2003-07-08 |
2006-11-30 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
NZ530852A
(en)
|
2001-08-27 |
2006-11-30 |
Genentech Inc |
Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells
|
HU230373B1
(hu)
|
2001-08-29 |
2016-03-29 |
Genentech Inc |
Mitogén aktivitású Bv8-nukleinsavak és polipeptidek
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
EP1456238B1
(en)
*
|
2001-12-17 |
2008-05-28 |
Crucell Holland B.V. |
Production of f(ab')2 fragments in mammalian cells
|
EP3960855A1
(en)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing proteins
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
EP1575480A4
(en)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
US7332276B2
(en)
|
2002-03-01 |
2008-02-19 |
Celltech R&D, Inc. |
Methods to increase or decrease bone density
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ATE428778T1
(de)
|
2002-04-26 |
2009-05-15 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening auf agonistische antikörper
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003239966B9
(en)
*
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7585501B2
(en)
|
2002-06-14 |
2009-09-08 |
Stowers Institute For Medical Research |
Compositions and methods for treating kidney disease
|
CA2489588A1
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CN104001181B
(zh)
|
2002-07-15 |
2017-05-10 |
得克萨斯大学体系董事会 |
与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗和诊断用途
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
US20040067532A1
(en)
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
EP2277532A1
(en)
|
2002-09-11 |
2011-01-26 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
CA2496060C
(en)
|
2002-09-11 |
2015-08-04 |
Genentech, Inc. |
Protein purification by ion exchange chromatography
|
CA2498274A1
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
EP1551292B1
(en)
*
|
2002-09-24 |
2016-04-27 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Imaging method for convection enhanced delivery of therapeutic agents
|
EP1585482A4
(en)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
EP1795595A1
(en)
|
2002-10-22 |
2007-06-13 |
Eisai R&D Management Co., Ltd. |
Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
WO2004039956A2
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
JP2006516094A
(ja)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
ナチュラルキラー細胞関連疾患の治療のための組成物と方法
|
ITMI20022411A1
(it)
*
|
2002-11-14 |
2004-05-15 |
Bracco Imaging Spa |
Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
|
JP4727992B2
(ja)
|
2002-11-15 |
2011-07-20 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
癌転移および癌転移に伴なう骨量減少を予防および処置するための方法
|
EP2258724A1
(en)
|
2002-11-21 |
2010-12-08 |
Celltech R & D, Inc. |
Modulating immune responses using multimerized anti-CD83 antibodies
|
EP2308968A1
(en)
|
2002-11-26 |
2011-04-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7056702B2
(en)
|
2002-12-16 |
2006-06-06 |
Kimberly Clark Co |
Detecting lipocalin
|
EP1585767A2
(en)
*
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
JP2006516624A
(ja)
|
2003-01-24 |
2006-07-06 |
エラン ファーマシューティカルズ,インコーポレイテッド |
脱髄疾患および麻痺のための組成物ならびに再有髄化剤を投与することによるそれらの治療
|
KR101118340B1
(ko)
|
2003-03-12 |
2012-04-12 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의용도
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
RS51686B
(sr)
|
2003-04-09 |
2011-10-31 |
Genentech Inc. |
Lečenje autoimune bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
AU2004252067B2
(en)
|
2003-05-09 |
2012-04-12 |
Duke University |
CD20-specific antibodies and methods of employing same
|
AU2004272972A1
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
WO2004111192A2
(en)
|
2003-05-29 |
2004-12-23 |
The Scripps Research Institute |
Targeted delivery to legumain-expressing cells
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
EP1642971B1
(en)
|
2003-06-18 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose transporter
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US20080075712A1
(en)
*
|
2003-10-14 |
2008-03-27 |
Kunihiro Hattori |
Double Specific Antibodies Substituting For Functional Proteins
|
US7304139B2
(en)
|
2003-10-28 |
2007-12-04 |
University Of Florida Research Foundation, Inc. |
Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
|
SG148161A1
(en)
|
2003-11-05 |
2008-12-31 |
Palingen Inc |
Enhanced b cell cytotoxicity of cdim binding antibody
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
PE20090047A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
WO2005048938A2
(en)
*
|
2003-11-13 |
2005-06-02 |
California Pacific Medical Center |
Anti-pecam therapy for metastasis suppression
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
EP1710255A4
(en)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
DK1716181T3
(da)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR-reparerede antistoffer
|
AU2005230848B9
(en)
|
2004-03-31 |
2011-06-02 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1769243A2
(en)
|
2004-05-15 |
2007-04-04 |
Genentech, Inc. |
Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
|
WO2005118864A2
(en)
|
2004-05-28 |
2005-12-15 |
Agensys, Inc. |
Antibodies and related molecules that bind to psca proteins
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
US7604947B2
(en)
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
AU2005267148A1
(en)
|
2004-07-01 |
2006-02-02 |
University Of Southern California |
Genetic markers for predicting disease and treatment outcome
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
ES2339789T3
(es)
|
2004-07-20 |
2010-05-25 |
Genentech, Inc. |
Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
|
US20080199437A1
(en)
|
2004-07-22 |
2008-08-21 |
Eisai Co., Ltd. |
Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
|
JP2008507520A
(ja)
|
2004-07-22 |
2008-03-13 |
ジェネンテック・インコーポレーテッド |
Her2抗体組成物
|
JP2008507294A
(ja)
|
2004-07-26 |
2008-03-13 |
ダウ グローバル テクノロジーズ インコーポレイティド |
菌株遺伝子操作による改善されたタンパク質発現のための方法
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
RU2431676C2
(ru)
|
2004-08-06 |
2011-10-20 |
Дженентек, Инк. |
Анализы и способы с применением биомаркеров
|
ATE508753T1
(de)
|
2004-08-06 |
2011-05-15 |
Genentech Inc |
Assays und verfahren unter verwendung von biomarkern
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
RU2412947C2
(ru)
|
2004-09-23 |
2011-02-27 |
Дженентек, Инк. |
Антитела, сконструированные на основе цистеинов, и их конъюгаты
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
SG165344A1
(en)
|
2004-10-05 |
2010-10-28 |
Genentech Inc |
Method for treating vasculitis
|
EP2251418B1
(en)
|
2004-10-07 |
2021-03-17 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
RS52539B
(en)
|
2004-10-21 |
2013-04-30 |
Genentech Inc. |
METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES
|
JP2008519030A
(ja)
|
2004-11-05 |
2008-06-05 |
パリンゲン インコーポレーテッド |
抗体で誘導される細胞膜損傷
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
WO2006067847A1
(ja)
|
2004-12-22 |
2006-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
|
US7947805B2
(en)
|
2004-12-23 |
2011-05-24 |
Merck Serono S.A. |
BCMA polypeptides and uses thereof
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
KR20190110637A
(ko)
|
2005-01-21 |
2019-09-30 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
AU2006208226A1
(en)
*
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
RU2404806C2
(ru)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
AU2006230563B8
(en)
|
2005-03-31 |
2010-06-17 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161P2F10B proteins
|
CA2957144C
(en)
|
2005-04-08 |
2020-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody substituting for function of blood coagulation factor viii
|
EP1879923B1
(en)
|
2005-04-09 |
2015-05-27 |
Fusion Antibodies Limited |
Cathepsin s antibody
|
ES2477765T3
(es)
|
2005-04-19 |
2014-07-17 |
Seattle Genetics, Inc. |
Agentes de unión al anti-cd70 humanizado y usos de los mismos
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
CN101212967A
(zh)
|
2005-05-10 |
2008-07-02 |
因塞特公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
EP2385061A3
(en)
|
2005-05-10 |
2012-02-22 |
Neoloch Aps |
Neuritogenic peptides
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
JP4931919B2
(ja)
|
2005-06-21 |
2012-05-16 |
ゾーマ テクノロジー リミテッド |
IL−1β結合抗体およびその断片
|
JP5171621B2
(ja)
|
2005-07-07 |
2013-03-27 |
シアトル ジェネティックス, インコーポレイテッド |
フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
|
HUE035853T2
(en)
|
2005-07-18 |
2018-05-28 |
Seattle Genetics Inc |
Beta-glucuronide-linker-drug conjugates
|
CN105012953B
(zh)
|
2005-07-25 |
2018-06-22 |
阿普泰沃研发有限责任公司 |
用cd37-特异性和cd20-特异性结合分子减少b-细胞
|
EP1913027B1
(en)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf specific monoclonal antibody and uses thereof
|
EP3006457B1
(en)
|
2005-07-29 |
2017-11-22 |
The Government of the United States of America, as represented by the Secretary of Health and Human Services |
Mutated pseudomonas exotoxins with reduced antigenicity
|
US7494648B2
(en)
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US7411046B2
(en)
*
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
*
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
*
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456259B2
(en)
*
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
KR101446025B1
(ko)
|
2005-08-03 |
2014-10-01 |
아이바이오, 인크. |
면역글로불린의 생산을 위한 조성물 및 방법
|
WO2007021860A2
(en)
|
2005-08-11 |
2007-02-22 |
Bayer Healthcare Llc |
QUANTITATIVE ASSAYS FOR PDGFR-β IN BODY FLUIDS
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
ATE533058T1
(de)
|
2005-08-16 |
2011-11-15 |
Genentech Inc |
Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
LT1931710T
(lt)
|
2005-08-31 |
2017-03-27 |
Merck Sharp & Dohme Corp. |
Rekombinantiniai anti-il-23 antikūnai
|
CN101296706B
(zh)
|
2005-09-01 |
2011-11-30 |
先灵公司 |
Il-23和il-17拮抗剂治疗自身免疫性眼部炎性疾病的用途
|
WO2007035716A2
(en)
|
2005-09-16 |
2007-03-29 |
Raptor Pharmaceutical Inc. |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
CA2624393C
(en)
|
2005-11-04 |
2016-01-05 |
Genentech, Inc. |
Use of complement pathway inhibitors to treat ocular diseases
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP2392589A3
(en)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
RS54111B1
(en)
|
2005-11-18 |
2015-12-31 |
Glenmark Pharmaceuticals S.A. |
ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
EP2567973B1
(en)
|
2005-11-28 |
2014-05-14 |
Zymogenetics, Inc. |
IL-21 antagonists
|
US8957187B2
(en)
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
EP1973950B1
(en)
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
EP1984024A2
(en)
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
EP2749571A3
(en)
|
2006-01-10 |
2014-08-13 |
ZymoGenetics, Inc. |
Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
|
US8277816B2
(en)
*
|
2006-02-13 |
2012-10-02 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
WO2007095320A2
(en)
*
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Hpv antigens, vaccine compositions, and related methods
|
CA2642054C
(en)
|
2006-02-13 |
2017-11-21 |
Fraunhofer Usa, Inc. |
Influenza antigens, vaccine compositions, and related methods
|
EP1989228B1
(en)
|
2006-02-14 |
2015-04-29 |
University Of Tasmania Through The Menzies Research Institute |
Metallothionein-derived peptide fragments
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
EP2010677A4
(en)
|
2006-02-24 |
2010-04-14 |
Investigen Inc |
METHODS AND COMPOSITIONS FOR DETECTION OF POLYNUCLEOTIDES
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AU2007226627B2
(en)
|
2006-03-10 |
2012-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
CA3022097C
(en)
|
2006-03-15 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
CA2646329C
(en)
*
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
TWI397535B
(zh)
|
2006-03-21 |
2013-06-01 |
Genentech Inc |
包含α5β1拮抗劑之組合治療
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
US9321838B2
(en)
|
2006-04-10 |
2016-04-26 |
Fusion Antibodies Limited |
Therapy targeting cathepsin S
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
EP3255149A3
(en)
|
2006-05-02 |
2018-04-18 |
Intrexon Actobiotics NV |
Microbial intestinal delivery of obesity related peptides
|
WO2007134050A2
(en)
*
|
2006-05-09 |
2007-11-22 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
EP2522678A1
(en)
|
2006-05-15 |
2012-11-14 |
Sea Lane Biotechnologies, LLC |
Neutralizing antibodies to influenza viruses
|
CA2652945C
(en)
|
2006-05-30 |
2015-06-02 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
US8796429B2
(en)
|
2006-05-31 |
2014-08-05 |
Lpath, Inc. |
Bioactive lipid derivatives, and methods of making and using same
|
US20080138334A1
(en)
|
2006-05-31 |
2008-06-12 |
Sabbadini Roger A |
Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
|
US9274130B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
EP2032604A2
(en)
|
2006-06-06 |
2009-03-11 |
Genentech, Inc. |
Anti-dll4 antibodies and methods using same
|
CA2654317A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
US20100040600A1
(en)
|
2006-06-14 |
2010-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for Promoting the Growth of Hematopoietic Stem Cells
|
US8874380B2
(en)
|
2010-12-09 |
2014-10-28 |
Rutgers, The State University Of New Jersey |
Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
|
JP5605895B2
(ja)
|
2006-07-04 |
2014-10-15 |
ゲンマブ エー/エス |
Copdを処置するためのcd20結合分子
|
AU2007273507A1
(en)
|
2006-07-13 |
2008-01-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death inducer
|
MX2009000696A
(es)
|
2006-07-19 |
2009-01-30 |
Univ Pennsylvania |
Wsx-1/p28 como un objetivo para respuestas anti-inflamatorias.
|
EP2057193B1
(en)
|
2006-08-04 |
2013-12-18 |
Novartis AG |
Ephb3-specific antibody and uses thereof
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
BRPI0713086A2
(pt)
|
2006-08-14 |
2012-10-09 |
Forerunner Pharma Res Co Ltd |
diagnóstico e tratamento de cáncer usando anticorpo anti-desmogleìna-3
|
TWI454480B
(zh)
|
2006-08-18 |
2014-10-01 |
Novartis Ag |
催乳激素受體(prlr)之專一性抗體及其用途
|
EP2059533B1
(en)
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
PT2061810E
(pt)
|
2006-09-05 |
2015-02-05 |
Alexion Pharma Inc |
Métodos e composições para o tratamento de neuropatias mediadas por anticorpos
|
ATE522625T1
(de)
|
2006-09-12 |
2011-09-15 |
Genentech Inc |
Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
|
RU2537245C2
(ru)
|
2006-10-12 |
2014-12-27 |
Чугаи Сейяку Кабусики Кайся |
Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
|
AU2007311946A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
WO2008047925A1
(fr)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
|
US7846434B2
(en)
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
PT2502938E
(pt)
|
2006-10-27 |
2015-06-05 |
Genentech Inc |
Anticorpos e imunoconjugados e suas utilizações
|
WO2008055072A2
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
MX2009004532A
(es)
|
2006-10-27 |
2009-09-04 |
Lpath Inc |
Composiciones y metodos para unir esfingosina-1-fosfato.
|
CA2668484A1
(en)
|
2006-11-13 |
2008-05-22 |
F. Hoffmann-La Roche Ag |
Cancerous disease modifying antibodies 180706-02
|
EP3156415A1
(en)
|
2006-11-22 |
2017-04-19 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
CA2672581A1
(en)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
KR20090088950A
(ko)
|
2006-12-14 |
2009-08-20 |
쉐링 코포레이션 |
가공된 항-tslp 항체
|
TW200831538A
(en)
|
2006-12-19 |
2008-08-01 |
Genentech Inc |
VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
|
CA2673592C
(en)
|
2006-12-20 |
2014-03-25 |
Xoma Technology Ltd. |
Methods for the treatment of il-1.beta. related diseases
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
WO2008084402A2
(en)
|
2007-01-11 |
2008-07-17 |
Philipps-Universitaet Marburg |
Diagnosis and treatment of alzheimer's and other neurodementing diseases
|
EP2111553B1
(en)
|
2007-01-24 |
2018-09-19 |
Carnegie Mellon University |
Optical biosensors
|
JP2010517529A
(ja)
*
|
2007-02-02 |
2010-05-27 |
アムジエン・インコーポレーテツド |
ヘプシジン及びヘプシジン抗体
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
EP3246407B1
(en)
|
2007-02-09 |
2019-04-03 |
Eisai R&D Management Co., Ltd. |
Gaba neuron progenitor cell marker 65b13
|
US20100216977A1
(en)
|
2007-02-15 |
2010-08-26 |
Kyushu University, National University Corporation |
Therapeutic agent for interstitial pulmonary disease comprising anti-hmgb-1 antibody
|
CA2678451A1
(en)
|
2007-02-20 |
2008-08-28 |
Robert A. Horlick |
Somatic hypermutation systems
|
ES2708988T3
(es)
|
2007-02-23 |
2019-04-12 |
Merck Sharp & Dohme |
Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
|
CN101663320A
(zh)
|
2007-02-23 |
2010-03-03 |
先灵公司 |
工程改造的抗IL-23p19抗体
|
US7771947B2
(en)
|
2007-02-23 |
2010-08-10 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
JP5374360B2
(ja)
|
2007-02-27 |
2013-12-25 |
中外製薬株式会社 |
抗grp78抗体を有効成分として含む医薬組成物
|
CN101668531B
(zh)
|
2007-02-28 |
2014-05-07 |
默沙东公司 |
用于治疗免疫病症的联合治疗
|
KR20100014568A
(ko)
|
2007-02-28 |
2010-02-10 |
쉐링 코포레이션 |
가공된 항-il-23r 항체
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
US20090068684A1
(en)
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
SI2644205T1
(sl)
|
2007-04-12 |
2018-11-30 |
The Brigham And Women's Hospital, Inc. |
Ciljanje ABCB5 za zdravljenje raka
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
BRPI0810120A2
(pt)
|
2007-04-27 |
2014-11-11 |
Dow Global Technologies Inc |
Processo para selecionar rapidamente hospedeiros microbianos para a identificação de certas cepas com maior rendimento e/ou qualidade na expressão de proteínas heterólogas
|
EP2150564A2
(en)
|
2007-04-27 |
2010-02-10 |
ZymoGenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
US8778348B2
(en)
|
2007-04-28 |
2014-07-15 |
Ibio Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US20080280778A1
(en)
*
|
2007-05-03 |
2008-11-13 |
Urdea Michael S |
Binding reagents that contain small epitope binding molecules
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
KR101729431B1
(ko)
|
2007-05-21 |
2017-04-21 |
제넨테크, 인크. |
루푸스를 확인 및 치료하기 위한 방법 및 조성물
|
DK2164992T3
(da)
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
Sammensætninger og fremgangsmåder til binding af lysophosphatidsyre
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
CA2690124A1
(en)
|
2007-06-07 |
2008-12-18 |
Genentech, Inc. |
C3b antibodies and methods for the prevention and treatment of complement-associated disorders
|
WO2008154249A2
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
EP2167130A2
(en)
*
|
2007-07-06 |
2010-03-31 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
AU2008275229B2
(en)
|
2007-07-09 |
2014-11-06 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
WO2009009759A2
(en)
|
2007-07-11 |
2009-01-15 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
JP5749009B2
(ja)
|
2007-08-13 |
2015-07-15 |
バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. |
EphB4に結合するヒト化抗体を利用する癌治療剤
|
CA2696764A1
(en)
*
|
2007-08-20 |
2009-02-26 |
Fraunhofer Usa, Inc. |
Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
|
CA2698343C
(en)
*
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
PT2197903E
(pt)
|
2007-09-04 |
2015-01-02 |
Us Gov Health & Human Serv |
Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
US7704508B2
(en)
|
2007-09-14 |
2010-04-27 |
New York Blood Center |
Babesia subtilisin
|
EP2192922A4
(en)
|
2007-09-17 |
2010-09-29 |
Univ California |
INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGING PROSTATE <I> IN SITU CANCER CELLS </ I>
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
EP3789400A1
(en)
|
2007-09-26 |
2021-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
EP2205280B1
(en)
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
NZ583944A
(en)
|
2007-09-28 |
2012-06-29 |
Portola Pharm Inc |
Antidotes for factor xa inhibitors and methods of using the same
|
CA2700410C
(en)
*
|
2007-10-03 |
2020-10-06 |
Cornell University |
Treatment of proliferative disorders using antibodies to psma
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
US8361465B2
(en)
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
CA2703279C
(en)
|
2007-10-30 |
2014-04-22 |
Genentech, Inc. |
Antibody purification by cation exchange chromatography
|
LT2514436T
(lt)
|
2007-11-07 |
2018-04-10 |
Genentech, Inc. |
Il-22 panaudojimas mikrobinių sutrikimų gydymui
|
JP2011503094A
(ja)
|
2007-11-08 |
2011-01-27 |
ジェネンテック, インコーポレイテッド |
抗b因子抗体およびそれらの使用
|
EP2730282A1
(en)
|
2007-11-08 |
2014-05-14 |
The General Hospital Corporation |
Methods and compositions for the treatment of proteinuric diseases
|
DK2219672T3
(da)
|
2007-11-09 |
2016-05-17 |
Peregrine Pharmaceuticals Inc |
Anti-vegf-antistofsammensætninger og fremgangsmåder
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
KR20100097691A
(ko)
|
2007-11-12 |
2010-09-03 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
WO2009063970A1
(ja)
|
2007-11-14 |
2009-05-22 |
Forerunner Pharma Research Co., Ltd. |
抗gpr49抗体を用いる癌の診断および治療
|
RU2559530C2
(ru)
|
2007-11-15 |
2015-08-10 |
Чугаи Сейяку Кабусики Кайся |
Моноклональные антитела, способные связываться с белком axl, и их применение
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
EP2728017B1
(en)
|
2007-11-19 |
2016-08-24 |
Celera Corporation |
Lung cancer markers and uses thereof
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
CN101970689A
(zh)
|
2007-11-29 |
2011-02-09 |
健泰科生物技术公司 |
炎性肠病的基因表达标志物
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
KR101643005B1
(ko)
|
2007-12-05 |
2016-07-28 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
GB0723797D0
(en)
|
2007-12-05 |
2008-01-16 |
Immunosolv Ltd |
Method
|
PT2391650E
(pt)
|
2007-12-20 |
2015-01-14 |
Xoma Us Llc |
Métodos para o tratamento de gota
|
WO2009085200A2
(en)
|
2007-12-21 |
2009-07-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
CN101918450A
(zh)
|
2008-01-11 |
2010-12-15 |
国立大学法人东京大学 |
抗cldn6抗体
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
WO2009094551A1
(en)
|
2008-01-25 |
2009-07-30 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MX2010008437A
(es)
|
2008-01-31 |
2010-11-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
MX2010009885A
(es)
|
2008-03-10 |
2010-11-30 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
|
WO2009117531A1
(en)
|
2008-03-18 |
2009-09-24 |
Seattle Genetics, Inc. |
Auristatin drug linker conjugates
|
WO2009120922A2
(en)
|
2008-03-27 |
2009-10-01 |
Zymogenetics, Inc. |
Compositions and methods for inhibiting pdgfrbeta and vegf-a
|
US20100040635A1
(en)
|
2008-03-28 |
2010-02-18 |
Sea Lane Biotechnologies |
Neutralizing antibodies to influenza viruses
|
WO2009124294A2
(en)
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
EP2279412B1
(en)
|
2008-04-09 |
2017-07-26 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP2011516078A
(ja)
|
2008-04-10 |
2011-05-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
癌におけるegfr突然変異を検出する組成物および方法
|
EP2365003A1
(en)
*
|
2008-04-11 |
2011-09-14 |
Emergent Product Development Seattle, LLC |
CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
EP2116555A1
(en)
|
2008-05-08 |
2009-11-11 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
EP2319869B1
(en)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
|
US8460657B2
(en)
|
2008-06-25 |
2013-06-11 |
H. Lundbeck A/S |
Modulation of the TrpV: Vps10p receptor system for the treatment of pain
|
WO2010006601A1
(en)
|
2008-06-30 |
2010-01-21 |
Dako Denmark A/S |
Pax 5 monoclonal antibody
|
SI2824100T1
(en)
|
2008-07-08 |
2018-06-29 |
Incyte Holdings Corporation |
1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
ES2613841T3
(es)
|
2008-07-16 |
2017-05-26 |
Medical And Biological Laboratories Co., Ltd. |
Anticuerpo anti-CLCP1 humano y uso del mismo
|
US8148088B2
(en)
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
EP2633864A1
(en)
|
2008-07-25 |
2013-09-04 |
The Regents of the University of Colorado |
Clip inhibitors and methods of modulating immune function
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
DK2848625T3
(da)
|
2008-08-14 |
2019-10-07 |
Genentech Inc |
Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
AR073538A1
(es)
|
2008-09-03 |
2010-11-17 |
Genentech Inc |
Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
CA2748995C
(en)
|
2008-10-07 |
2018-01-16 |
Bracco Suisse Sa |
Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
|
MX2011003618A
(es)
|
2008-10-09 |
2011-06-16 |
Tufts College |
Peliculas de seda modificadas que contienen glicerol.
|
KR102100066B1
(ko)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
JP5775458B2
(ja)
|
2008-11-06 |
2015-09-09 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
抗α2インテグリン抗体を使用する処置
|
US8710104B2
(en)
|
2008-11-07 |
2014-04-29 |
Triact Therapeutics, Inc. |
Catecholic butanes and use thereof for cancer therapy
|
TW201029663A
(en)
|
2008-11-12 |
2010-08-16 |
Theraclone Sciences Inc |
Human M2e peptide immunogens
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
CA2742871C
(en)
|
2008-11-13 |
2018-10-23 |
Herb Lin |
Methods and compositions for regulating iron homeostasis by modulation of bmp-6
|
ATE523603T1
(de)
|
2008-11-21 |
2011-09-15 |
Chimera Biotec Gmbh |
Konjugatkomplexe zum analytnachweis
|
JP6041489B2
(ja)
|
2008-11-22 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
乳癌の治療のための化学療法と併用した抗vegf抗体の使用
|
US9273133B2
(en)
|
2008-12-04 |
2016-03-01 |
Lankenau Institute For Medical Research |
Compositions and methods for the treatment and prevention of lens fibrotic diseases
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
US20110250644A1
(en)
|
2008-12-19 |
2011-10-13 |
Schering Corporation |
Feed supplement for mammalian cell culture and methods of use
|
JP5756292B2
(ja)
|
2008-12-22 |
2015-07-29 |
中外製薬株式会社 |
抗hs6st2抗体及びその用途
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP5523346B2
(ja)
|
2008-12-22 |
2014-06-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Neph3を用いた膵臓前駆細胞の取得方法
|
BRPI0918204A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
igv variante composição farmaceutica e kit
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
WO2010073694A1
(ja)
|
2008-12-25 |
2010-07-01 |
国立大学法人東京大学 |
抗tm4sf20抗体を用いた癌の診断と治療
|
BRPI0923652A2
(pt)
|
2008-12-26 |
2016-10-18 |
Forerunner Pharma Res Co Ltd |
diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
|
WO2010078376A2
(en)
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
ES2712732T3
(es)
*
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
GB0902916D0
(en)
|
2009-02-20 |
2009-04-08 |
Fusion Antibodies Ltd |
Antibody therapy
|
GB0903168D0
(en)
|
2009-02-25 |
2009-04-08 |
Fusion Antibodies Ltd |
Diagnostic method and kit
|
CA2919467C
(en)
|
2009-03-02 |
2018-04-17 |
Jan Paul Medema |
Antibodies against a proliferating inducing ligand (april)
|
AR075715A1
(es)
*
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
EP2230515B1
(en)
|
2009-03-16 |
2014-12-17 |
Agilent Technologies, Inc. |
Passivation of surfaces after ligand coupling
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
TW201544123A
(zh)
|
2009-03-20 |
2015-12-01 |
Genentech Inc |
抗-her抗體
|
US20120121591A1
(en)
|
2009-03-20 |
2012-05-17 |
Amgen Inc. |
SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
|
UA108199C2
(uk)
|
2009-03-25 |
2015-04-10 |
|
АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
|
EP2679600A1
(en)
|
2009-03-25 |
2014-01-01 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
EP2233496A1
(en)
|
2009-03-26 |
2010-09-29 |
Ruhr-Universität Bochum |
Fluorescent proteins
|
EP3604510A1
(en)
|
2009-03-30 |
2020-02-05 |
Portola Pharmaceuticals, Inc. |
Antidotes for factor xa inhibitors and methods of using the same
|
JP5795306B2
(ja)
|
2009-04-01 |
2015-10-14 |
ジェネンテック, インコーポレイテッド |
インスリン抵抗性疾患の治療
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
RU2598248C2
(ru)
|
2009-04-02 |
2016-09-20 |
Роше Гликарт Аг |
Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US9079957B2
(en)
|
2009-04-16 |
2015-07-14 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
|
CA2759506A1
(en)
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
PE20120562A1
(es)
|
2009-05-15 |
2012-06-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-axl
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2436397B1
(en)
|
2009-05-29 |
2017-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition containing antagonist of egf family ligand as component
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
GB0909906D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Antibodies
|
EP2445531A4
(en)
|
2009-06-24 |
2013-04-24 |
Lpath Inc |
PROCESS FOR INCREASED NEURONAL DIFFERENTIATION USING ANTIBODIES TO LYSOPHOSPHACIDIC ACID
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
WO2011005715A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
ES2605801T3
(es)
|
2009-07-15 |
2017-03-16 |
Portola Pharmaceuticals, Inc. |
Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
|
EP2456890A1
(en)
|
2009-07-20 |
2012-05-30 |
Genentech, Inc. |
Gene expression markers for crohn's disease
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
WO2011014750A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
IN2012DN00863A
(da)
|
2009-07-31 |
2015-07-10 |
Medarex Inc |
|
HUE038451T2
(hu)
|
2009-08-06 |
2018-10-29 |
Hoffmann La Roche |
Eljárás vírus eltávolításának javítására fehérjetisztítás során
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
CA2770321A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Biological markers for monitoring patient response to vegf antagonists
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
WO2011022264A1
(en)
|
2009-08-15 |
2011-02-24 |
Genentech, Inc. |
Anti-angiogenesis therapy for the treatment of previously treated breast cancer
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
CA2772240C
(en)
|
2009-08-17 |
2017-12-05 |
Tracon Pharmaceuticals, Inc. |
Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
|
EP2468771A4
(en)
|
2009-08-17 |
2013-06-05 |
Forerunner Pharma Res Co Ltd |
PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY TO HB-EGF AS AN ACTIVE SUBSTANCE
|
AU2010288469A1
(en)
|
2009-08-31 |
2012-03-01 |
Roche Glycart Ag |
Affinity-matured humanized anti CEA monoclonal antibodies
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
KR20170119746A
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
WO2011032022A1
(en)
|
2009-09-11 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
EP2475996A1
(en)
|
2009-09-11 |
2012-07-18 |
F. Hoffmann-La Roche AG |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
SG179196A1
(en)
|
2009-09-16 |
2012-04-27 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
MX2012002909A
(es)
|
2009-09-17 |
2012-04-19 |
Hoffmann La Roche |
Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
CA2776144C
(en)
|
2009-09-29 |
2020-10-27 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
PE20120998A1
(es)
|
2009-09-30 |
2012-08-14 |
Genentech Inc |
Metodos para el tratamiento del cancer usando antagonistas de notch
|
KR101953075B1
(ko)
|
2009-10-07 |
2019-02-27 |
제넨테크, 인크. |
루푸스의 치료, 진단 및 모니터링 방법
|
EP2488643A4
(en)
|
2009-10-15 |
2013-07-03 |
Hoffmann La Roche |
CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY
|
US8435511B2
(en)
|
2009-10-22 |
2013-05-07 |
Genentech, Inc. |
Anti-hepsin antibodies and methods using same
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
EP2322149A1
(en)
|
2009-11-03 |
2011-05-18 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of ischemia
|
CN102782149B
(zh)
|
2009-11-04 |
2014-11-12 |
默沙东公司 |
经工程改造的抗-tslp抗体
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
KR101968766B1
(ko)
|
2009-11-05 |
2019-04-12 |
제넨테크, 인크. |
이종 폴리펩티드의 분비를 위한 방법 및 조성물
|
EP2497498A4
(en)
|
2009-11-05 |
2013-04-17 |
Univ Osaka |
THERAPEUTIC ACTIVE FOR AUTOIMMUNE DISEASES OR ALLERGIES AND METHOD FOR SCREENING AFTER THE THERAPEUTIC ACTIVE SUBSTANCE
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
RU2012124093A
(ru)
|
2009-11-12 |
2013-12-20 |
Дженентек, Инк. |
Способ увеличения плотности дендритных шипиков
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
TW201129379A
(en)
|
2009-11-20 |
2011-09-01 |
Amgen Inc |
Anti-Orai1 antigen binding proteins and uses thereof
|
RS56469B1
(sr)
|
2009-11-24 |
2018-01-31 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
MX354143B
(es)
|
2009-12-02 |
2018-02-14 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
MX2012006560A
(es)
|
2009-12-08 |
2012-10-05 |
Abbott Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
EP2513308B1
(en)
|
2009-12-17 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Modulation of pilr to treat immune disorders
|
WO2011084750A1
(en)
|
2009-12-21 |
2011-07-14 |
Genentech, Inc. |
Antibody formulation
|
GB0922553D0
(en)
|
2009-12-23 |
2010-02-10 |
Fusion Antibodies Ltd |
Prognostic marker
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
EP2338492A1
(en)
|
2009-12-24 |
2011-06-29 |
Universidad del Pais Vasco |
Methods and compositions for the treatment of alzheimer
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
PL2530091T3
(pl)
|
2010-01-29 |
2018-08-31 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciało przeciwko dll3
|
CN102712769B
(zh)
|
2010-01-29 |
2014-12-03 |
东丽株式会社 |
聚乳酸系树脂片
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
GB201002238D0
(en)
|
2010-02-10 |
2010-03-31 |
Affitech As |
Antibodies
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
US8877897B2
(en)
|
2010-02-23 |
2014-11-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP3696194A1
(en)
|
2010-02-23 |
2020-08-19 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
WO2011105573A1
(ja)
|
2010-02-26 |
2011-09-01 |
株式会社未来創薬研究所 |
抗icam3抗体およびその用途
|
US20130004516A1
(en)
|
2010-03-04 |
2013-01-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Drug for inflammatory bowel disease
|
KR20180000342A
(ko)
|
2010-03-22 |
2018-01-02 |
제넨테크, 인크. |
단백질-함유 제제의 안정화에 유용한 조성물 및 방법
|
KR101899835B1
(ko)
|
2010-03-24 |
2018-09-19 |
제넨테크, 인크. |
항-lrp6 항체
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
CA2796633C
(en)
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
CN103068378B
(zh)
|
2010-05-10 |
2016-07-06 |
中央研究院 |
具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
|
HUE033315T2
(en)
|
2010-05-14 |
2017-11-28 |
Amgen Inc |
High concentration antibody preparations
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US9995679B2
(en)
|
2010-05-25 |
2018-06-12 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
SG185737A1
(en)
|
2010-05-25 |
2013-01-30 |
Genentech Inc |
Methods of purifying polypeptides
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
AU2011259924A1
(en)
|
2010-06-02 |
2013-01-24 |
Sumitomo Dainippon Pharma Co., Ltd. |
Treatment drug for autoimmune diseases and allergic diseases
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
PT2580240T
(pt)
|
2010-06-14 |
2019-03-29 |
Lykera Biomed S A |
Anticorpos as100a4 e utilizações terapêuticas dos mesmos
|
EP2582729A4
(en)
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
SI3586826T1
(sl)
|
2010-06-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
JP2013533871A
(ja)
|
2010-06-30 |
2013-08-29 |
ノヴォ ノルディスク アー/エス |
組織因子経路インヒビターに特異的に結合することが可能な抗体
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
SG187120A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
KR20130049196A
(ko)
|
2010-08-05 |
2013-05-13 |
에프. 호프만-라 로슈 아게 |
항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
|
CA2807673A1
(en)
|
2010-08-10 |
2012-02-16 |
Xinyi Cynthia Chen |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
CR20180142A
(es)
|
2010-08-13 |
2018-04-05 |
Roche Glycart Ag |
ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
ES2555864T3
(es)
|
2010-08-19 |
2016-01-11 |
F. Hoffmann-La Roche Ag |
Ensayo para la medición de anticuerpos de unión a un anticuerpo monoclonal terapéutico
|
WO2012027440A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CN103080132B
(zh)
|
2010-08-25 |
2016-06-08 |
弗·哈夫曼-拉罗切有限公司 |
抗il-18r1的抗体及其用途
|
KR101518144B1
(ko)
|
2010-08-27 |
2015-05-28 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 9에 대한 항체
|
CA3201524A1
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
DK2612151T3
(da)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
Biomarkører og fremgangsmåder til behandling
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
JP6159660B2
(ja)
|
2010-09-22 |
2017-07-05 |
アムジエン・インコーポレーテツド |
担体としての免疫グロブリンおよびその使用
|
TWI764324B
(zh)
|
2010-09-29 |
2022-05-11 |
美商艾澤西公司 |
與191p4d12蛋白結合之抗體藥物共軛物(adc)
|
DK2625197T3
(da)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened-mutant og fremgangsmåder til anvendelse af samme
|
EP2629836B1
(en)
|
2010-10-19 |
2018-09-12 |
Trustees Of Tufts College |
Silk fibroin-based microneedles and methods of making the same
|
EP2632481A1
(en)
|
2010-10-25 |
2013-09-04 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
WO2012061129A1
(en)
|
2010-10-25 |
2012-05-10 |
Genentech, Inc |
Treatment of gastrointestinal inflammation and psoriasis a
|
EP2632489B1
(en)
|
2010-10-27 |
2020-01-15 |
The Research Foundation for The State University of New York |
Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
|
CN103201393B
(zh)
|
2010-11-01 |
2019-01-18 |
霍夫曼-拉罗奇有限公司 |
使用多基因计分预测向晚期老年性黄斑变性的进展
|
US20130302364A1
(en)
|
2010-11-10 |
2013-11-14 |
Laboratorios Del Dr. Esteve, S.A. |
Highly immunogenic hiv p24 sequences
|
EP2638070B1
(en)
|
2010-11-10 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Methods and compositions for neural disease immunotherapy
|
DK2644698T3
(da)
|
2010-11-17 |
2018-01-22 |
Chugai Pharmaceutical Co Ltd |
Multispecifikt antigen-bindende molekyle med alternativ funktion til funktion af blodkoagulationsfaktor viii
|
WO2012099566A1
(en)
|
2010-11-17 |
2012-07-26 |
Sea Lane Biotechnologies, Llc |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
GB201020738D0
(en)
|
2010-12-07 |
2011-01-19 |
Affitech Res As |
Antibodies
|
AR084342A1
(es)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
Diagnostico y tratamientos relacionados con la inhibicion de th2
|
JP6253987B2
(ja)
|
2010-12-20 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
抗メソテリン抗体及びイムノコンジュゲート
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
DK2663580T3
(da)
|
2011-01-10 |
2017-03-13 |
Ct Atlantic Ltd |
Kombinationsterapi omfattende tumorassocierede antigenbindende antistoffer
|
EP2663857B1
(en)
|
2011-01-11 |
2018-12-12 |
The Governing Council Of The University Of Toronto |
Protein detection method
|
PT2665746T
(pt)
|
2011-01-17 |
2021-02-03 |
Lykera Biomed S A |
Anticorpos contra a proteína s100p para o tratamento e diagnóstico de cancro
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
KR101913448B1
(ko)
|
2011-02-04 |
2018-10-30 |
제넨테크, 인크. |
Fc 변이체 및 그의 생산 방법
|
EP2673283B1
(en)
|
2011-02-09 |
2017-08-23 |
Roche Diagnostics GmbH |
New iridium-based complexes for ecl
|
EP2673284B1
(en)
|
2011-02-09 |
2017-08-30 |
Roche Diagnostics GmbH |
New iridium-based complexes for ecl
|
WO2012107416A2
(en)
|
2011-02-10 |
2012-08-16 |
Roche Glycart Ag |
Improved immunotherapy
|
EP3971206A1
(en)
|
2011-02-10 |
2022-03-23 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
EP2673297A2
(en)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
WO2012112489A2
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
LT2681244T
(lt)
|
2011-03-02 |
2018-02-12 |
Roche Glycart Ag |
Cea antikūnai
|
CN103429256B
(zh)
|
2011-03-02 |
2022-09-13 |
诺和诺德保健股份有限公司 |
凝血因子向活化的血小板上的tlt-1的靶向
|
JP6385060B2
(ja)
|
2011-03-07 |
2018-09-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
治療的に活性な抗体のインビボにおける選択
|
US20140099264A1
(en)
|
2011-03-07 |
2014-04-10 |
F. Hoffman-La Roche Ag |
Means and methods for in vivo testing of therapeutic antibodies
|
CA2826811A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Apex1 as marker for chronic obstructive pulmonary disease (copd)
|
JP6170840B2
(ja)
|
2011-03-11 |
2017-07-26 |
ベス イスラエル デアコネス メディカル センター インコーポレイテッド |
抗cd40抗体及びその使用
|
ES2583684T3
(es)
|
2011-03-11 |
2016-09-21 |
F. Hoffmann-La Roche Ag |
ARMET como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
|
CN103403555B
(zh)
|
2011-03-11 |
2015-06-24 |
霍夫曼-拉罗奇有限公司 |
Asc作为慢性阻塞性肺病(copd)的标志物
|
CA2826812A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Fen1 as marker for chronic obstructive pulmonary disease (copd)
|
WO2012123297A1
(en)
|
2011-03-11 |
2012-09-20 |
Roche Diagnostics Gmbh |
Nnmt as marker for chronic obstructive pulmonary disease (copd)
|
JP2014509736A
(ja)
|
2011-03-11 |
2014-04-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
慢性閉塞性肺疾患(copd)のマーカーとしてのセプラーゼ
|
WO2012125614A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PE20140593A1
(es)
|
2011-03-16 |
2014-05-10 |
Amgen Inc |
Inhibidores potentes y selectivos de nav1.3 y nav1.7
|
EP2689252A1
(en)
|
2011-03-25 |
2014-01-29 |
Roche Diagnostics GmbH |
MEASUREMENT OF C-TERMINAL proSP-B
|
BR112013024521A2
(pt)
|
2011-03-25 |
2019-09-24 |
Genentech Inc |
métodos de purificação de proteínas
|
WO2012130831A1
(en)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Antibody fc variants
|
EP3412309A1
(en)
|
2011-03-31 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Methods of administering beta7 integrin antagonists
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
US10059746B2
(en)
|
2011-04-04 |
2018-08-28 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
US20140186340A1
(en)
|
2011-04-08 |
2014-07-03 |
Gilead Biologics, Inc. |
Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
|
EP2700652B1
(en)
|
2011-04-18 |
2018-12-19 |
The University of Tokyo |
Diagnosis and treatment of cancer using anti-itm2a antibody
|
WO2012145652A1
(en)
|
2011-04-20 |
2012-10-26 |
Trustees Of Tufts College |
Dynamic silk coatings for implantable devices
|
CN103502273A
(zh)
|
2011-04-20 |
2014-01-08 |
罗氏格黎卡特股份公司 |
用于pH依赖性通过血脑屏障的方法和构建体
|
JP6170906B2
(ja)
|
2011-04-21 |
2017-07-26 |
トラスティーズ・オブ・タフツ・カレッジTrustees Of Tufts College |
活性物質を安定化させるための組成物および方法
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
ME02858B
(me)
|
2011-05-02 |
2018-04-20 |
Millennium Pharm Inc |
Formulacija za anti- 4 7 antitelo
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
SG194787A1
(en)
|
2011-05-06 |
2013-12-30 |
Us Gov Health & Human Serv |
Recombinant immunotoxin targeting mesothelin
|
US10273291B2
(en)
|
2011-05-09 |
2019-04-30 |
Duke University |
Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
|
JP5987053B2
(ja)
|
2011-05-12 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法
|
MX370233B
(es)
|
2011-05-16 |
2019-12-06 |
Genentech Inc |
Antagonistas de fgfr1 y sus metodos de uso.
|
JP6323718B2
(ja)
|
2011-05-17 |
2018-05-16 |
ザ ロックフェラー ユニバーシティー |
ヒト免疫不全ウイルスを無毒化する抗体、およびその使用方法。
|
EP2714742A1
(en)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Magea3 binding antibodies
|
EP2714743A1
(en)
|
2011-06-03 |
2014-04-09 |
CT Atlantic Ltd. |
Magea3 binding antibodies
|
ES2894398T3
(es)
|
2011-06-03 |
2022-02-14 |
Xoma Technology Ltd |
Anticuerpos específicos para TGF-beta
|
JP6100764B2
(ja)
|
2011-06-09 |
2017-03-22 |
アメリカ合衆国 |
免疫原性の低いt細胞及び/又はb細胞エピトープを有するシュードモナス外毒素a
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
BR112013032217B1
(pt)
|
2011-06-17 |
2021-01-19 |
Novo Nordisk A/S |
uso de um anticorpo anti-nkg2a
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
WO2013011061A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
WO2013011062A2
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Oscar antagonists
|
WO2013011059A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonist antibodies against oscar
|
WO2013011063A1
(en)
|
2011-07-18 |
2013-01-24 |
Novo Nordisk A/S |
Antagonistic antibodies against oscar
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
CN103842030B
(zh)
|
2011-08-01 |
2018-07-31 |
霍夫曼-拉罗奇有限公司 |
使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
CN103890007A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
神经调节蛋白抗体及其用途
|
US20150017091A1
(en)
|
2011-08-18 |
2015-01-15 |
Cornell University |
Detection and treatment of metastatic disease
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
PT2748202T
(pt)
|
2011-08-23 |
2018-10-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas
|
HUE038225T2
(hu)
|
2011-08-23 |
2018-10-29 |
Roche Glycart Ag |
Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
|
RU2014109038A
(ru)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
Антитела к хондроитинсульфат протеогликану меланомы
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
US10018630B2
(en)
|
2011-09-07 |
2018-07-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell isolation
|
SG11201400100SA
(en)
|
2011-09-09 |
2014-06-27 |
Univ Osaka |
Dengue-virus serotype neutralizing antibodies
|
MX2014003094A
(es)
|
2011-09-15 |
2014-04-25 |
Genentech Inc |
Metodos para promover diferenciacion.
|
WO2013040141A1
(en)
|
2011-09-16 |
2013-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with less immunogenic b cell epitopes
|
BR112014006419A2
(pt)
|
2011-09-19 |
2018-08-07 |
Genentech Inc |
métodos para tratar um paciente com câncer, kit e artigo
|
CN107287660A
(zh)
|
2011-09-30 |
2017-10-24 |
中外制药株式会社 |
离子浓度依赖性结合分子文库
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
US9575073B2
(en)
|
2011-10-10 |
2017-02-21 |
Rutgers, The State University Of New Jersey |
Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
|
PL2766397T3
(pl)
|
2011-10-11 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Ulepszone składanie przeciwciał bispecyficznych
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
PT2766393T
(pt)
|
2011-10-14 |
2018-10-15 |
Hoffmann La Roche |
Anticorpos anti-htra1 e métodos de utilização
|
EP2581388A1
(en)
|
2011-10-14 |
2013-04-17 |
Centre National de la Recherche Scientifique (CNRS) |
Anti-sPLA2-V antibodies and uses thereof
|
RU2014119426A
(ru)
|
2011-10-15 |
2015-11-20 |
Дженентек, Инк. |
Способы применения антагонистов scd1
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
RU2014120577A
(ru)
|
2011-10-26 |
2015-12-10 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний
|
US20140302511A1
(en)
|
2011-10-28 |
2014-10-09 |
Pharmalogicals Research Pte. Ltd. |
Cancer stem cell-specific molecule
|
AR088509A1
(es)
|
2011-10-28 |
2014-06-11 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
WO2013067301A1
(en)
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
WO2013067639A1
(en)
|
2011-11-07 |
2013-05-16 |
UNIVERSITé LAVAL |
Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
|
WO2013070907A1
(en)
|
2011-11-08 |
2013-05-16 |
Tufts University |
A silk-based scaffold platform for engineering tissue constructs
|
EP2788040B1
(en)
|
2011-11-09 |
2023-05-24 |
Trustees Of Tufts College |
Injectable silk fibroin particles and uses thereof
|
EP3750567A1
(en)
|
2011-11-09 |
2020-12-16 |
Trustees of Tufts College |
Injectable silk fibroin foams and uses thereof
|
KR101733853B1
(ko)
|
2011-11-17 |
2017-05-08 |
화이자 인코포레이티드 |
세포독성 펩티드 및 그의 항체 약물 접합체
|
MX2014005885A
(es)
|
2011-11-21 |
2014-09-04 |
Genentech Inc |
Purificacion de anticuerpos anti-c-met.
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
MX350807B
(es)
|
2011-11-29 |
2017-09-20 |
Genentech Inc |
Composiciones y metodos para el analisis de cancer de prostata.
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
EP2602265A1
(en)
|
2011-12-07 |
2013-06-12 |
Centre National de la Recherche Scientifique (CNRS) |
Antibodies anti-sPLA2-X and uses thereof
|
AU2012352168C1
(en)
|
2011-12-14 |
2018-01-25 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CA2855570A1
(en)
|
2011-12-14 |
2013-06-20 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
SG11201403223PA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
WO2013096851A1
(en)
|
2011-12-22 |
2013-06-27 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
MY172426A
(en)
|
2011-12-22 |
2019-11-25 |
Genentech Inc |
Ion exchange membrane chromatography
|
SG10201700169PA
(en)
|
2011-12-22 |
2017-02-27 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
BR112014016154A8
(pt)
|
2011-12-29 |
2017-07-04 |
Tufts College |
funcionalização de biomateriais para controlar respostas à regeneração e inflamação
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
JP2015504674A
(ja)
|
2012-01-11 |
2015-02-16 |
アリゾナ ボード オブ リージェンツ ア ボディ コーポレート オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティーArizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
神経疾患タンパク質の二重特異性抗体フラグメントおよび使用方法
|
EP2802346B1
(en)
|
2012-01-13 |
2018-09-12 |
F.Hoffmann-La Roche Ag |
Biological markers for identifying patients for treatment with vegf antagonists
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
RS57603B1
(sr)
|
2012-01-27 |
2018-11-30 |
Abbvie Deutschland |
Sastav i metod za dijagnozu i tretiranje bolesti povezanih sa degeneracijom neurita
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
TWI606064B
(zh)
|
2012-02-08 |
2017-11-21 |
Igm生物科技公司 |
細胞死亡誘導分子(cdim)結合蛋白類及彼等之用途
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
JP6152120B2
(ja)
|
2012-02-15 |
2017-06-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体に基づくアフィニティークロマトグラフィー
|
SG10201610788VA
(en)
|
2012-02-29 |
2017-03-30 |
Gilead Biologics Inc |
Antibodies to matrix metalloproteinase 9
|
US9550836B2
(en)
|
2012-02-29 |
2017-01-24 |
Gilead Biologics, Inc. |
Method of detecting human matrix metalloproteinase 9 using antibodies
|
MX2014010379A
(es)
|
2012-03-02 |
2015-05-15 |
Roche Glycart Ag |
Biomarcador predictivo para tratamiento de cancer con anticuerpos mejorados en adcc.
|
CA2866881A1
(en)
|
2012-03-09 |
2013-09-12 |
Lankenau Institute For Medical Research |
Compositions and methods for treating cancer
|
KR102143887B1
(ko)
|
2012-03-16 |
2020-08-12 |
유니버시티 헬스 네트워크 |
Toso 활성을 조절하기 위한 방법 및 조성물
|
WO2013142119A1
(en)
|
2012-03-20 |
2013-09-26 |
Trustees Of Tufts College |
Silk reservoirs for drug delivery
|
EP2641916A1
(en)
|
2012-03-23 |
2013-09-25 |
Centre National de la Recherche Scientifique (C.N.R.S) |
Novel antibodies anti-sPLA2-IIA and uses thereof
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
JP6335875B2
(ja)
|
2012-03-30 |
2018-05-30 |
ジェネンテック, インコーポレイテッド |
癌の治療のための診断法及び組成物
|
EP3492095A1
(en)
|
2012-04-01 |
2019-06-05 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
EP2836236B1
(en)
|
2012-04-13 |
2019-01-02 |
Trustees Of Tufts College |
Methods and compositions for preparing a silk microsphere
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
EP2841108A4
(en)
|
2012-04-25 |
2015-11-25 |
Tufts College |
SILK MICROSPHERES AND SURFACE LUBRICATION METHODS
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
EP3795215A1
(en)
|
2012-05-30 |
2021-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
SG10201603055WA
(en)
|
2012-05-31 |
2016-05-30 |
Genentech Inc |
Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists
|
MX2014014830A
(es)
|
2012-06-15 |
2015-05-11 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
CA2872192A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
BR112014030843A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo
|
CN110042114A
(zh)
|
2012-07-05 |
2019-07-23 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
IN2014DN10652A
(da)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
BR112015000441A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
CN104411337A
(zh)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
MA37794B1
(fr)
|
2012-07-13 |
2017-07-31 |
Roche Glycart Ag |
Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
RU2015105588A
(ru)
|
2012-07-19 |
2016-09-10 |
Редвуд Байосайнс, Инк. |
Антитело, специфическое к cd22, и способы его применения
|
JP2015525781A
(ja)
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の調節
|
CN107602620B
(zh)
|
2012-08-02 |
2020-08-28 |
霍夫曼-拉罗奇有限公司 |
用于ecl的新型铱基络合物
|
ES2622998T3
(es)
|
2012-08-02 |
2017-07-10 |
F. Hoffmann-La Roche Ag |
Nuevos complejos basados en iridio para EQL
|
WO2014019707A2
(en)
|
2012-08-02 |
2014-02-06 |
Roche Diagnostics Gmbh |
New iridium-based complexes for ecl
|
JP2015530979A
(ja)
|
2012-08-02 |
2015-10-29 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Ecl用の新規イリジウムベース錯体
|
WO2014019710A1
(en)
|
2012-08-02 |
2014-02-06 |
Roche Diagnostics Gmbh |
New bis-iridium-complexes for manufacturing of ecl-labels
|
TR201816437T4
(tr)
|
2012-08-07 |
2018-11-21 |
Roche Glycart Ag |
Azalmış ve artmış efektör fonksiyonuna sahip olacak şekilde tasarlanmış iki antikor içeren bileşim.
|
BR112015002085A2
(pt)
|
2012-08-08 |
2017-12-19 |
Roche Glycart Ag |
proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
|
CN109705218B
(zh)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
SI2885010T1
(sl)
|
2012-08-16 |
2020-07-31 |
Ipierian, Inc. |
Metode zdravljenja tauopatije
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
EA201990839A1
(ru)
|
2012-08-23 |
2019-08-30 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
WO2014051022A1
(ja)
|
2012-09-27 |
2014-04-03 |
中外製薬株式会社 |
Fgfr3融合遺伝子およびそれを標的とする医薬
|
AU2013326974B2
(en)
|
2012-10-03 |
2019-01-03 |
Zymeworks Bc Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
CA2884368C
(en)
|
2012-10-05 |
2022-01-18 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
CA2888659A1
(en)
|
2012-10-18 |
2014-04-24 |
Rockefeller University (The) |
Broadly-neutralizing anti-hiv antibodies
|
CA2889170C
(en)
|
2012-10-25 |
2021-09-07 |
True North Therapeutics, Inc. |
Anti-complement c1s antibodies and uses thereof
|
CA2889208A1
(en)
|
2012-10-30 |
2014-05-08 |
Gilead Sciences, Inc. |
Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
|
CN108610418B
(zh)
|
2012-11-02 |
2022-11-01 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
PL2917195T3
(pl)
|
2012-11-05 |
2018-04-30 |
Pfizer Inc. |
Analogi spliceostatyny
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
TWI589590B
(zh)
|
2012-11-07 |
2017-07-01 |
輝瑞股份有限公司 |
抗切口3(anti-notch3)抗體及抗體-藥物共軛體
|
US9725512B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
HER3 antibodies binding to the beta-hairpin of HER3
|
MA38176A1
(fr)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
|
BR112015011011A2
(pt)
|
2012-11-15 |
2019-12-17 |
Genentech Inc |
cromatografia por troca de íon com gradiente de ph mediada por força iônica
|
US10550171B2
(en)
|
2012-11-21 |
2020-02-04 |
The Governors Of The University Of Alberta |
Immunomodulatory peptides and methods of use thereof
|
PT2928923T
(pt)
|
2012-12-10 |
2020-03-27 |
Biogen Ma Inc |
Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
EP2767549A1
(en)
|
2013-02-19 |
2014-08-20 |
Adienne S.A. |
Anti-CD26 antibodies and uses thereof
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
KR20150122761A
(ko)
|
2013-02-26 |
2015-11-02 |
로슈 글리카트 아게 |
T 세포 활성화 항원 결합 분자
|
SG11201504497TA
(en)
|
2013-02-26 |
2015-09-29 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
UY35397A
(es)
|
2013-03-12 |
2014-10-31 |
Amgen Inc |
INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
EP3744345B1
(en)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
CN105209058A
(zh)
|
2013-03-13 |
2015-12-30 |
豪夫迈·罗氏有限公司 |
具有降低的氧化的配制物
|
SG10201705525VA
(en)
|
2013-03-13 |
2017-08-30 |
Genentech Inc |
Formulations with reduced oxidation
|
WO2014151917A1
(en)
|
2013-03-14 |
2014-09-25 |
Ffe Therapeutics Llc |
Compositions and methods for treating angiogenesis-related disorders
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
CA2903480A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
CN105143265A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
抗CRTh2抗体及其用途
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
CA2903091C
(en)
|
2013-03-15 |
2022-09-06 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the generation and use of conformation-specific antibodies
|
WO2014152177A1
(en)
|
2013-03-15 |
2014-09-25 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
BR112015023262B8
(pt)
|
2013-03-15 |
2024-02-06 |
Ac Immune Sa |
Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
KR102158924B1
(ko)
|
2013-03-15 |
2020-09-22 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
US10119134B2
(en)
|
2013-03-15 |
2018-11-06 |
Abvitro Llc |
Single cell bar-coding for antibody discovery
|
EP2968544A4
(en)
|
2013-03-15 |
2016-10-12 |
Hoffmann La Roche |
CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
|
SG11201507427QA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
WO2014152006A2
(en)
|
2013-03-15 |
2014-09-25 |
Intrinsic Lifesciences, Llc |
Anti-hepcidin antibodies and uses thereof
|
ES2926773T3
(es)
|
2013-03-15 |
2022-10-28 |
Novo Nordisk As |
Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
|
ES2759061T3
(es)
|
2013-03-15 |
2020-05-07 |
Biomolecular Holdings Llc |
Inmunoglobulina híbrida que contiene unión no peptidílica
|
JP6574754B2
(ja)
|
2013-03-19 |
2019-09-11 |
ベイジン シェノゲン ファーマ グループ リミテッド |
エストロゲン受容体関連疾患を処置するための抗体及び方法
|
EP3495814A3
(en)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
EP2984108B1
(en)
|
2013-04-09 |
2017-05-31 |
Lykera Biomed, S.A. |
Anti-s100a7 antibodies for the treatment and diagnosis of cancer
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
SG10201800800YA
(en)
|
2013-05-06 |
2018-03-28 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
EP2999716A2
(en)
|
2013-05-20 |
2016-03-30 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
WO2014192915A1
(ja)
|
2013-05-30 |
2014-12-04 |
国立大学法人 千葉大学 |
抗ミオシン調節軽鎖ポリペプチド抗体を含む炎症疾患治療用組成物
|
EP3632467B1
(en)
|
2013-06-07 |
2023-09-27 |
Duke University |
Inhibitors of complement factor h
|
HUE050485T2
(hu)
|
2013-06-10 |
2020-12-28 |
Ipierian Inc |
Tauopathia kezelési módszerei
|
WO2014200767A1
(en)
|
2013-06-12 |
2014-12-18 |
The General Hospital Corporation |
Methods, kits, and systems for multiplexed detection of target molecules and uses thereof
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
BR112015032414A2
(pt)
|
2013-06-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico compreendendo anticorpo antiepirregulina humanizado como ingrediente ativo para carcinoma de pulmão de célula não pequena excluindo adenocarcinoma
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015001082A1
(en)
|
2013-07-05 |
2015-01-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
EP3019240B1
(en)
|
2013-07-09 |
2024-03-13 |
Annexon, Inc. |
Anti-complement factor c1q antibodies and uses thereof
|
KR102251127B1
(ko)
|
2013-07-12 |
2021-05-11 |
제넨테크, 인크. |
이온 교환 크로마토그래피 입력 최적화의 설명
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
ES2819209T3
(es)
|
2013-07-16 |
2021-04-15 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN113583128A
(zh)
|
2013-08-01 |
2021-11-02 |
鲁汶大学 |
抗garp蛋白及其用途
|
SG11201600587VA
(en)
|
2013-08-01 |
2016-02-26 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
WO2015016718A1
(en)
|
2013-08-02 |
2015-02-05 |
Bionovion Holding B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
EP3039042A1
(en)
|
2013-08-29 |
2016-07-06 |
University of Copenhagen |
Anti-adam12 antibodies for the treatment of cancer
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
JP2016531920A
(ja)
|
2013-09-05 |
2016-10-13 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
|
MX2016002798A
(es)
|
2013-09-05 |
2016-07-21 |
Genentech Inc |
Metodo para reutilizacion de cromatografia.
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
EP3042208A4
(en)
|
2013-09-06 |
2017-04-19 |
Theranos, Inc. |
Systems and methods for detecting infectious diseases
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
EP3044323B1
(en)
|
2013-09-13 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Methods for detecting and quantifying host cell protein in cell lines
|
MX2016003202A
(es)
|
2013-09-13 |
2016-06-07 |
Genentech Inc |
Metodos y composiciones que comprenden polipeptidos recombinantes purificados.
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
MA38960A1
(fr)
|
2013-09-27 |
2017-10-31 |
Genentech Inc |
Formulations d'anticorps anti-pdl1
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
CA2922950A1
(en)
|
2013-09-30 |
2015-04-02 |
Shinya Ishii |
Method for producing antigen-binding molecule using modified helper phage
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
WO2015054670A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
RU2016119425A
(ru)
|
2013-10-23 |
2017-11-28 |
Дженентек, Инк. |
Способы диагностики и лечения эозинофильных заболеваний
|
EP3063317B1
(en)
|
2013-10-28 |
2020-06-03 |
DOTS Technology Corp. |
Allergen detection
|
WO2015067755A2
(en)
|
2013-11-07 |
2015-05-14 |
Novo Nordisk A/S |
Novel methods and antibodies for treating coagulapathy
|
JPWO2015068847A1
(ja)
|
2013-11-11 |
2017-03-09 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
JP6993083B2
(ja)
|
2013-11-15 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
環境適合性洗浄剤を使用するウイルス不活性化方法
|
WO2015076282A1
(ja)
|
2013-11-20 |
2015-05-28 |
国立大学法人北海道大学 |
免疫制御剤
|
EP3071597B1
(en)
|
2013-11-21 |
2020-07-29 |
F.Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
JP6879739B2
(ja)
|
2013-11-25 |
2021-06-02 |
フェイムウェイヴ リミテッド |
癌治療のための抗ceacam1および抗pd抗体を含む組成物
|
EP2876114A1
(en)
|
2013-11-25 |
2015-05-27 |
Consejo Superior De Investigaciones Científicas |
Antibodies against CCR9 and applications thereof
|
EP3074039A4
(en)
|
2013-11-26 |
2017-10-11 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
CN105899230B
(zh)
|
2013-11-27 |
2020-06-09 |
伊皮埃里安股份有限公司 |
治疗tau病变的方法
|
SG10201906981TA
(en)
|
2013-12-03 |
2019-09-27 |
Harvard College |
Methods and reagents for the assessment of gestational diabetes
|
TWI664331B
(zh)
|
2013-12-04 |
2019-07-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
WO2015089375A1
(en)
|
2013-12-13 |
2015-06-18 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
NZ720515A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
MX2016007958A
(es)
|
2013-12-17 |
2016-08-03 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso.
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
JP6622703B2
(ja)
|
2013-12-20 |
2019-12-18 |
インターベット インターナショナル ベー. フェー. |
アンタゴニストの、抗イヌpd−1抗体
|
MX2016006529A
(es)
|
2013-12-20 |
2016-08-03 |
Genentech Inc |
Anticuerpos dobles especificos.
|
PL3083680T3
(pl)
|
2013-12-20 |
2020-06-29 |
F. Hoffmann-La Roche Ag |
Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
DK3087986T3
(da)
|
2013-12-27 |
2019-12-02 |
Chugai Pharmaceutical Co Ltd |
Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme
|
WO2015102341A1
(ko)
|
2013-12-30 |
2015-07-09 |
재단법인 의약바이오컨버젼스연구단 |
항 krs 모노클로날 항체 및 이의 용도
|
CN105873616B
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
共价连接的多肽毒素-抗体缀合物
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP2896400A1
(en)
|
2014-01-17 |
2015-07-22 |
Université Catholique De Louvain |
Method for increasing the bioavailability of inhaled compounds
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016015693A2
(pt)
|
2014-01-24 |
2017-10-24 |
Genentech Inc |
método para tratar um câncer de próstata e anticorpo
|
EP3099692B9
(en)
|
2014-01-27 |
2019-11-13 |
Pfizer Inc |
Bifunctional cytotoxic agents
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
DK3102197T3
(da)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened-mutant og fremgangsmåder til anvendelse deraf
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
PL3102230T3
(pl)
|
2014-02-08 |
2021-11-15 |
F.Hoffmann-La Roche Ag |
Sposoby leczenia choroby Alzheimera
|
AR099465A1
(es)
|
2014-02-12 |
2016-07-27 |
Genentech Inc |
Anticuerpos anti-jagged1 y métodos de uso
|
US10106623B2
(en)
|
2014-02-12 |
2018-10-23 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
MX2016010729A
(es)
|
2014-02-21 |
2016-10-26 |
Genentech Inc |
Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
|
MX2016011177A
(es)
|
2014-02-27 |
2016-12-16 |
Gilead Sciences Inc |
Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
|
KR20160127817A
(ko)
|
2014-03-07 |
2016-11-04 |
유니버시티 헬스 네트워크 |
면역 반응을 변형시키기 위한 방법 및 조성물
|
PT3116909T
(pt)
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
AU2015229186B2
(en)
|
2014-03-14 |
2021-01-28 |
Biomolecular Holdings Llc |
Hybrid immunoglobulin containing non-peptidyl linkage
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
WO2015140351A1
(en)
|
2014-03-21 |
2015-09-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing myelination
|
EP3119913B1
(en)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
AR099856A1
(es)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
MA51552A
(fr)
|
2014-03-31 |
2021-03-24 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation
|
RU2688627C2
(ru)
|
2014-03-31 |
2019-05-22 |
Университетет И Тромсё - Норгес Арктиске Университет |
АНТИТЕЛА К HPA-1a
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
EP3125936B1
(en)
|
2014-03-31 |
2019-05-08 |
Debiopharm International SA |
Fgfr fusions
|
US9995746B2
(en)
|
2014-04-02 |
2018-06-12 |
The United States Of America, As Represented By The Secretary Of The Army |
Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
|
US20150361163A1
(en)
|
2014-04-18 |
2015-12-17 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
CA2983796A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
RS60106B1
(sr)
|
2014-04-25 |
2020-05-29 |
Bluebird Bio Inc |
Mnd promoterni himerni antigenski receptori
|
NZ725201A
(en)
|
2014-04-25 |
2018-05-25 |
Bluebird Bio Inc |
Improved methods for manufacturing adoptive cell therapies
|
MX366359B
(es)
|
2014-04-27 |
2019-07-05 |
Ccam Biotherapeutics Ltd |
Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
WO2015171822A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
WO2015171938A1
(en)
|
2014-05-08 |
2015-11-12 |
Novodiax, Inc. |
Direct immunohistochemistry assay
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184008A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
CN106714830B
(zh)
|
2014-05-30 |
2020-08-25 |
上海复宏汉霖生物技术股份有限公司 |
抗表皮生长因子受体(egfr)抗体
|
NZ726989A
(en)
|
2014-06-06 |
2020-08-28 |
Bluebird Bio Inc |
Improved t cell compositions
|
CA2949234C
(en)
|
2014-06-09 |
2022-03-22 |
Ultragenyx Pharmaceutical Inc. |
Anti-fgf23 antibody for treatment of hypophosphatemic disorders
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
MX2016016295A
(es)
|
2014-06-11 |
2017-03-31 |
Gilead Sciences Inc |
Metodos para tratar enfermedades cardiovasculares.
|
US10106579B2
(en)
|
2014-06-12 |
2018-10-23 |
Ra Pharmaceuticals, Inc. |
Modulation of complement activity
|
EP3154589A1
(en)
|
2014-06-13 |
2017-04-19 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
EP3154566B1
(en)
|
2014-06-13 |
2022-08-03 |
Acceleron Pharma Inc. |
Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
|
CA2947504A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
EP3680336A1
(en)
|
2014-07-03 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Polypeptide expression systems
|
TWI727427B
(zh)
|
2014-07-09 |
2021-05-11 |
英屬開曼群島商博笛生物科技有限公司 |
用於治療腫瘤的抗pd-1組合
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
JP7032929B2
(ja)
|
2014-07-11 |
2022-03-09 |
ヴェンタナ メディカル システムズ, インク. |
抗pd-l1抗体及びその診断上の使用
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
PE20170263A1
(es)
|
2014-08-04 |
2017-03-30 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
US20170240631A1
(en)
|
2014-08-08 |
2017-08-24 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
RS63364B1
(sr)
|
2014-08-11 |
2022-07-29 |
Acerta Pharma Bv |
Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
PT3183268T
(pt)
|
2014-08-19 |
2020-05-15 |
Novartis Ag |
Recetor de antigénio quimérico (car) anti-cd123 para uso no tratamento de cancro
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
AP2017009765A0
(en)
|
2014-08-19 |
2017-02-28 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
WO2016026143A1
(en)
|
2014-08-22 |
2016-02-25 |
Huiru Wang |
Saccharide-based biomarkers and therapeutics
|
JP7286267B2
(ja)
|
2014-08-28 |
2023-06-05 |
バイオアトラ インコーポレイテッド |
修飾t細胞に対する条件的活性型キメラ抗原受容体
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
JP7085837B2
(ja)
|
2014-09-12 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び免疫複合体
|
KR102541849B1
(ko)
|
2014-09-15 |
2023-06-09 |
에이비비트로, 엘엘씨 |
고-처리량 뉴클레오티드 라이브러리 서열결정
|
CA2959545A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
US10934362B2
(en)
|
2014-09-15 |
2021-03-02 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
PL3110447T3
(pl)
|
2014-09-16 |
2020-10-19 |
Synermore Biologics Co., Ltd. |
Przeciwciało anty-EGFR i jego zastosowania
|
KR20170055521A
(ko)
|
2014-09-17 |
2017-05-19 |
제넨테크, 인크. |
항-her2 항체를 포함하는 면역콘주게이트
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
LT3262071T
(lt)
|
2014-09-23 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b imunokonjugatų naudojimo būdai
|
TWI701435B
(zh)
|
2014-09-26 |
2020-08-11 |
日商中外製藥股份有限公司 |
測定fviii的反應性之方法
|
TWI700300B
(zh)
|
2014-09-26 |
2020-08-01 |
日商中外製藥股份有限公司 |
中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
WO2016059113A1
(en)
|
2014-10-14 |
2016-04-21 |
Deutsches Krebsforschungszentrum |
Norovirus antibodies
|
MX2017004810A
(es)
|
2014-10-14 |
2017-10-16 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
KR20170075793A
(ko)
|
2014-11-05 |
2017-07-03 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
SI3215525T1
(sl)
|
2014-11-05 |
2020-11-30 |
Genentech, Inc. |
Postopki produkcije dvoverižnih proteinov v bakterijah
|
SG11201703667SA
(en)
|
2014-11-05 |
2017-06-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
CN107073126A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和tigit抑制剂的组合疗法
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
EP3218403B1
(en)
|
2014-11-10 |
2020-05-13 |
F.Hoffmann-La Roche Ag |
Anti-interleukin-33 antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
HUE049982T2
(hu)
|
2014-11-14 |
2020-11-30 |
Hoffmann La Roche |
TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
|
CN107429075B
(zh)
|
2014-11-17 |
2022-11-01 |
卡内基梅隆大学 |
可激活的双组份光敏剂
|
BR112017010198A2
(pt)
|
2014-11-17 |
2017-12-26 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
BR112017010268B1
(pt)
|
2014-11-19 |
2024-01-16 |
P & M Venge Ab |
Agente de ligação, composição de diagnóstico, kit de diagnóstico, método de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral, métodos para descartar uma infecção bacteriana ou viral em um indivíduo, métodos para considerar uma infecção bacteriana ou viral em um indivíduo, método para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo, método para descartar uma doença infecciosa, método para identificação do tipo de infecção e dispositivo para o diagnóstico de infecções bacterianas
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
WO2016081808A1
(en)
|
2014-11-20 |
2016-05-26 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
US20170327584A1
(en)
|
2014-11-26 |
2017-11-16 |
Millennium Pharmaceuticals, Inc. |
Vedolizumab for the Treatment of Fistulizing Crohn's Disease
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
US9975949B2
(en)
|
2014-12-05 |
2018-05-22 |
Genentech, Inc. |
Anti-CD79b antibodies and methods of use
|
EP3227337A1
(en)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
US10383929B2
(en)
|
2014-12-12 |
2019-08-20 |
Bluebird Bio, Inc. |
BCMA chimeric antigen receptors
|
EP3234601B1
(en)
|
2014-12-18 |
2019-10-09 |
Roche Diagnostics GmbH |
Methods for reducing interferences
|
ES2870983T3
(es)
|
2014-12-19 |
2021-10-28 |
Univ Nantes |
Anticuerpos anti-IL-34
|
PT3233921T
(pt)
|
2014-12-19 |
2021-12-09 |
Chugai Pharmaceutical Co Ltd |
Anticorpos anti-c5 e processos para a sua utilização
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
EP3236994A1
(en)
|
2014-12-23 |
2017-11-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Alpha-cell re-generation combined with conversion to beta cells
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
US9937222B2
(en)
|
2015-01-28 |
2018-04-10 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
WO2016125017A1
(en)
|
2015-02-03 |
2016-08-11 |
Universite Catholique De Louvain |
Anti-garp protein and uses thereof
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
US9969800B2
(en)
|
2015-02-05 |
2018-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
IL-8 antibodies
|
HRP20220890T1
(hr)
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
US10800846B2
(en)
|
2015-02-26 |
2020-10-13 |
Merck Patent Gmbh |
PD-1/PD-L1 inhibitors for the treatment of cancer
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
MA41636A
(fr)
|
2015-03-06 |
2018-01-09 |
Millennium Pharm Inc |
Méthode de traitement de la cholangite sclérosante primitive
|
EP3265557B1
(en)
|
2015-03-06 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Ultrapurified dsba and dsbc and methods of making and using the same
|
US20180057588A1
(en)
|
2015-03-16 |
2018-03-01 |
Aarhus Universitet |
Antibodies Towards an Extracellular Region of NBCn1
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
CN107531798B
(zh)
|
2015-03-20 |
2022-02-18 |
奥胡斯大学 |
Pcsk9的抑制剂用于脂蛋白代谢病症的治疗
|
SG11201706991YA
(en)
|
2015-03-20 |
2017-10-30 |
Pfizer |
Bifunctional cytotoxic agents containing the cti pharmacophore
|
US20180111989A1
(en)
|
2015-04-01 |
2018-04-26 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
CA2980087A1
(en)
|
2015-04-02 |
2016-10-06 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
EP3277314A4
(en)
|
2015-04-03 |
2018-08-29 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
CA2981711A1
(en)
|
2015-04-06 |
2016-10-13 |
Subdomain, Llc |
De novo binding domain containing polypeptides and uses thereof
|
WO2016164089A2
(en)
|
2015-04-06 |
2016-10-13 |
Acceleron Pharma Inc. |
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
HRP20230093T1
(hr)
|
2015-04-06 |
2023-03-31 |
Bioverativ Usa Inc. |
Humanizirana anti-c1s protutijela i postupci njihove primjene
|
DK3280441T3
(da)
|
2015-04-07 |
2021-11-15 |
Alector Llc |
Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
KR102057767B1
(ko)
|
2015-04-17 |
2019-12-19 |
에프. 호프만-라 로슈 아게 |
응고 인자 및 다중특이적 항체의 조합 요법
|
CN108064343B
(zh)
|
2015-04-21 |
2021-07-09 |
基因泰克公司 |
用于前列腺癌分析的组合物和方法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
WO2016179003A1
(en)
|
2015-05-01 |
2016-11-10 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
JP7048319B2
(ja)
|
2015-05-12 |
2022-04-05 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
ES2956662T3
(es)
|
2015-05-12 |
2023-12-26 |
Syntimmune Inc |
Anticuerpos anti-FcRn humanizados con afinidad madurada
|
WO2016184987A1
(en)
|
2015-05-19 |
2016-11-24 |
Yaya Diagnostics Gmbh |
Means and methods for the enrichment of nucleic acids
|
CN107921126A
(zh)
|
2015-05-22 |
2018-04-17 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
EP3303391A1
(en)
|
2015-05-26 |
2018-04-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
|
WO2016189118A1
(en)
|
2015-05-28 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
CA2985818A1
(en)
|
2015-05-31 |
2016-12-08 |
Curegenix Corporation |
Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy
|
WO2016193299A1
(en)
|
2015-06-01 |
2016-12-08 |
Medigene Immunotherapies Gmbh |
T cell receptor library
|
AU2016273214B2
(en)
|
2015-06-01 |
2018-10-18 |
Medigene Immunotherapies Gmbh |
Method for generating antibodies against T cell receptor
|
NZ737851A
(en)
|
2015-06-01 |
2019-08-30 |
Medigene Immunotherapies Gmbh |
T-cell receptor specific antibodies
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
US10112990B2
(en)
|
2015-06-05 |
2018-10-30 |
Genentech, Inc. |
Anti-Tau antibodies and methods of use
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
MX2017014740A
(es)
|
2015-06-08 |
2018-08-15 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
SG10201912085WA
(en)
|
2015-06-12 |
2020-02-27 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
CR20180031A
(es)
|
2015-06-16 |
2018-05-07 |
Genentech Inc |
Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
CA2989586A1
(en)
|
2015-06-16 |
2016-12-22 |
Pfizer, Inc. |
Pd-l1 antagonist combination treatments
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
US9862763B2
(en)
|
2015-06-24 |
2018-01-09 |
Hoffmann-La Roche Inc. |
Humanized anti-tau(pS422) antibodies and methods of use
|
WO2017001350A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
WO2017011275A1
(en)
|
2015-07-10 |
2017-01-19 |
Nersissian Aram M |
Factor viii protein compositions and methods of treating hemophilia a
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
CA2993009A1
(en)
|
2015-07-31 |
2017-02-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
EP3331536A4
(en)
|
2015-08-03 |
2019-03-27 |
The Regents of The University of California |
COMPOSITIONS AND METHODS FOR MODULATING ABHD2 ACTIVITY
|
EP3331550B1
(en)
|
2015-08-04 |
2022-11-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
NZ739560A
(en)
|
2015-08-05 |
2024-01-26 |
Acticor Biotech |
Novel anti-human gpvi antibodies and uses thereof
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
WO2017021023A1
(en)
|
2015-08-06 |
2017-02-09 |
Yaya Diagnostics Gmbh |
Means and methods for the detection of targets
|
EP4137158A1
(en)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
MX2018001644A
(es)
|
2015-08-11 |
2018-11-09 |
Wuxi Biologics Cayman Inc |
Anticuerpos anti-pd-1 novedosos.
|
EP3130922A1
(en)
|
2015-08-11 |
2017-02-15 |
Roche Diagnostics GmbH |
Alkaline pretreatment of parvoviruses for immunoassays
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
BR112018001956A2
(pt)
|
2015-08-20 |
2018-09-11 |
Hoffmann La Roche |
?método de medição de analitos e kit?
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
JP6920786B2
(ja)
|
2015-08-26 |
2021-08-18 |
ドイチェス クレブスフォルシュンクスツェントルム |
免疫ウイルス療法のためのrnaウイルス
|
EP3932953A1
(en)
|
2015-08-28 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Anti-hypusine antibodies and uses thereof
|
KR20180054639A
(ko)
|
2015-08-28 |
2018-05-24 |
알렉터 엘엘씨 |
항-siglec-7 항체 및 이의 사용 방법
|
EP3344295B1
(en)
|
2015-08-31 |
2022-02-23 |
Helixmith Co., Ltd. |
Anti-sialyl tn chimeric antigen receptors
|
JP7074341B2
(ja)
|
2015-09-02 |
2022-05-24 |
イムテップ エス.アー.エス. |
抗lag-3抗体
|
US10407484B2
(en)
|
2015-09-02 |
2019-09-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating T-cell mediated immune response
|
ES2924071T3
(es)
|
2015-09-02 |
2022-10-04 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
|
PT3307322T
(pt)
|
2015-09-04 |
2021-04-23 |
Primatope Therapeutics Inc |
Anticorpos anti-cp40 humanizados e as suas utilizações referência cruzada relativa às aplicações associadas
|
US10935544B2
(en)
|
2015-09-04 |
2021-03-02 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
MX2018003183A
(es)
|
2015-09-15 |
2018-08-23 |
Amgen Inc |
Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
|
JP6266164B2
(ja)
|
2015-09-18 |
2018-01-31 |
中外製薬株式会社 |
Il−8に結合する抗体およびその使用
|
WO2017046335A1
(en)
|
2015-09-18 |
2017-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes
|
EA201890613A1
(ru)
|
2015-09-21 |
2018-10-31 |
Аптево Рисёрч Энд Девелопмент Ллс |
Полипептиды, связывающие cd3
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
ES2940360T3
(es)
|
2015-09-22 |
2023-05-05 |
Inst Nat Sante Rech Med |
Polipéptidos capaces de inhibir la unión entre leptina y neuropilina-1
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
CA2999888C
(en)
|
2015-09-24 |
2024-04-09 |
Abvitro Llc |
Affinity-oligonucleotide conjugates and uses thereof
|
WO2017050955A1
(en)
|
2015-09-24 |
2017-03-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agents capable of inhibiting the binding between leptin and vegf165
|
MX2018003534A
(es)
|
2015-09-25 |
2019-04-25 |
Abvitro Llc |
Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
|
JP2018535655A
(ja)
|
2015-09-29 |
2018-12-06 |
アムジエン・インコーポレーテツド |
Asgr阻害剤
|
ES2839212T3
(es)
|
2015-09-29 |
2021-07-05 |
Inst Nat Sante Rech Med |
Métodos para determinar el estado metabólico de linfomas B
|
US20180282415A1
(en)
|
2015-09-30 |
2018-10-04 |
Merck Patent Gmbh |
Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
KR102072317B1
(ko)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
항-pd1 항체 및 사용 방법
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
EP3359572A2
(en)
|
2015-10-06 |
2018-08-15 |
H. Hoffnabb-La Roche Ag |
Method for treating multiple sclerosis
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
US10556953B2
(en)
|
2015-10-12 |
2020-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
WO2017070554A1
(en)
|
2015-10-23 |
2017-04-27 |
Fred Hutchinson Cancer Research Center |
Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
EP3368575A2
(en)
|
2015-10-29 |
2018-09-05 |
Alector LLC |
Anti-siglec-9 antibodies and methods of use thereof
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
JP6902185B2
(ja)
|
2015-11-03 |
2021-07-14 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Cd200阻害剤及びその使用方法
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
KR20180088381A
(ko)
|
2015-11-12 |
2018-08-03 |
시아맙 쎄라퓨틱스, 인코포레이티드 |
글리칸-상호작용 화합물 및 사용방법
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
EP3380121B1
(en)
|
2015-11-23 |
2023-12-20 |
Acceleron Pharma Inc. |
Actrii antagonist for use in treating eye disorders
|
EP3383920B1
(en)
|
2015-11-30 |
2024-01-10 |
The Regents of the University of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
WO2017097723A2
(en)
|
2015-12-09 |
2017-06-15 |
F. Hoffmann-La Roche Ag |
Treatment method
|
LT3390441T
(lt)
|
2015-12-15 |
2021-11-10 |
Gilead Sciences, Inc. |
Žmogaus imunodeficito virusą neutralizuojantys antikūnai
|
WO2017106578A1
(en)
|
2015-12-15 |
2017-06-22 |
Amgen Inc. |
Pacap antibodies and uses thereof
|
TWI745320B
(zh)
|
2015-12-16 |
2021-11-11 |
美商Ra製藥公司 |
補體活性之調節劑
|
US11045547B2
(en)
|
2015-12-16 |
2021-06-29 |
Merck Sharp & Dohme Corp. |
Anti-LAG3 antibodies and antigen-binding fragments
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
WO2017106806A1
(en)
|
2015-12-18 |
2017-06-22 |
Federica Cavallo |
COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
|
CA3005592C
(en)
|
2015-12-18 |
2024-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
CN108430511B
(zh)
|
2015-12-21 |
2021-06-04 |
合肥立方制药股份有限公司 |
一种药物设计方法和获得的药物及其应用
|
PL3394247T3
(pl)
|
2015-12-23 |
2021-08-23 |
Medigene Immunotherapies Gmbh |
Nowy sposób wytwarzania tcr swoistych wobec antygenu
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
WO2017117304A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
WO2017118634A1
(en)
|
2016-01-04 |
2017-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
|
ES2837428T3
(es)
|
2016-01-08 |
2021-06-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
|
JP7078536B2
(ja)
|
2016-01-08 |
2022-05-31 |
アルトゥルバイオ, インコーポレイテッド |
四価抗psgl-1抗体とその使用
|
HUE052893T2
(hu)
|
2016-01-13 |
2021-05-28 |
Acerta Pharma Bv |
Antifolát és BTK-gátló terápiás kombinációi
|
CN114113625A
(zh)
|
2016-01-20 |
2022-03-01 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
RU2021129189A
(ru)
|
2016-01-22 |
2021-11-15 |
Мерк Шарп И Доум Корп. |
Антитела против фактора свертывания xi
|
WO2017129558A1
(en)
|
2016-01-25 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
|
EP3408671B1
(en)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
ES2823173T3
(es)
|
2016-01-27 |
2021-05-06 |
Just Biotherapeutics Inc |
Promotor híbrido y usos del mismo
|
JP6902040B2
(ja)
|
2016-01-28 |
2021-07-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
免疫チェックポイント阻害剤の効力を増強する方法
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
WO2017129790A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancer
|
JP2019507126A
(ja)
|
2016-02-01 |
2019-03-14 |
ファイザー・インク |
ツブリシン類似体およびこれらの調製のための方法
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
WO2017139975A1
(en)
|
2016-02-19 |
2017-08-24 |
Huiru Wang |
Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
|
US11066456B2
(en)
|
2016-02-25 |
2021-07-20 |
Washington University |
Compositions comprising TREM2 and methods of use thereof
|
US10344067B2
(en)
|
2016-02-25 |
2019-07-09 |
Deutsches Krebsforschungszentrum |
RNA viruses expressing IL-12 for immunovirotherapy
|
US10982136B2
(en)
|
2016-02-26 |
2021-04-20 |
The Regents Of The University Of California |
Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
EP4043492A1
(en)
|
2016-03-01 |
2022-08-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Antibodies specific to human poliovirus receptor (pvr)
|
US20200281973A1
(en)
|
2016-03-04 |
2020-09-10 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11472877B2
(en)
|
2016-03-04 |
2022-10-18 |
Alector Llc |
Anti-TREM1 antibodies and methods of use thereof
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
ES2904286T3
(es)
|
2016-03-15 |
2022-04-04 |
Chugai Pharmaceutical Co Ltd |
Métodos de tratamiento de cánceres que emplean antagonistas que se unen al eje PD-1 y anticuerpos anti-GPC3
|
WO2017161169A1
(en)
|
2016-03-17 |
2017-09-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-py1235-met immunological binding reagent
|
PT3433280T
(pt)
|
2016-03-22 |
2023-06-15 |
Hoffmann La Roche |
Moléculas biespecíficas das células t ativadas pela protease
|
ES2947230T3
(es)
|
2016-03-22 |
2023-08-03 |
Hoffmann La Roche |
Moléculas biespecíficas para linfocitos T activadas por proteasa
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN111363041B
(zh)
|
2016-03-23 |
2022-02-22 |
苏州创胜医药集团有限公司 |
新型抗-pd-l1抗体
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
RS65129B1
(sr)
|
2016-03-28 |
2024-02-29 |
Incyte Corp |
Jedinjenja pirolotriazina kao inhibitori tam
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
US11768203B2
(en)
|
2016-03-31 |
2023-09-26 |
University Of Southern California |
Highly sensitive and specific luciferase based reporter assay for antigen detection
|
WO2017173327A1
(en)
|
2016-03-31 |
2017-10-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
CN109563158B
(zh)
|
2016-04-04 |
2022-08-09 |
比奥贝拉蒂美国公司 |
抗补体因子bb抗体以及其用途
|
EP3439659A1
(en)
|
2016-04-06 |
2019-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of age-related cardiometabolic diseases
|
WO2017177179A1
(en)
|
2016-04-08 |
2017-10-12 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
US10954287B2
(en)
|
2016-04-15 |
2021-03-23 |
Ra Pharmaceuticals, Inc. |
Ras binding peptides and methods of use
|
CA3021027A1
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
SG11201808994YA
(en)
|
2016-04-15 |
2018-11-29 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
EP3445779A1
(en)
|
2016-04-22 |
2019-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency
|
KR20190015704A
(ko)
|
2016-04-25 |
2019-02-14 |
신티뮨, 인크. |
인간화된 친화성 성숙 항-fcrn 항체
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
US11376269B2
(en)
|
2016-05-06 |
2022-07-05 |
Inserm |
Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (AML)
|
WO2017194586A1
(en)
|
2016-05-10 |
2017-11-16 |
Université Pierre Et Marie Curie - Paris 6 (Upmc) |
Agents that activate cd47 and their use in the treatment of inflammation
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
WO2017202962A1
(en)
|
2016-05-24 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
|
CA3025391A1
(en)
|
2016-05-26 |
2017-11-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for cancer treatment
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
WO2017202890A1
(en)
|
2016-05-27 |
2017-11-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating myeloma
|
KR102165623B1
(ko)
|
2016-05-31 |
2020-10-15 |
에프. 호프만-라 로슈 아게 |
바이러스 항원의 혈청학적 탐지 방법
|
EP3465216B1
(en)
|
2016-05-31 |
2020-04-08 |
Roche Diagnostics GmbH |
Pretreatment method for rapid detection of hcv core antigen
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
US10676536B2
(en)
|
2016-06-14 |
2020-06-09 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor XI antibodies
|
EP3472624B1
(en)
|
2016-06-15 |
2020-11-04 |
Roche Diagnostics GmbH |
Improved d-dimer assay calibration
|
AU2017286676A1
(en)
|
2016-06-17 |
2018-12-13 |
F. Hoffmann La-Roche Ag |
Purification of multispecific antibodies
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック, インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
DK3264087T3
(da)
|
2016-06-27 |
2020-07-20 |
Chimera Biotec Gmbh |
Fremgangsmåde og indretning til kvantificering af målmolekyler
|
CA3030841A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
US10722558B2
(en)
|
2016-07-15 |
2020-07-28 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
CN109803680A
(zh)
|
2016-08-01 |
2019-05-24 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
KR20190036551A
(ko)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
JP2018058822A
(ja)
|
2016-08-03 |
2018-04-12 |
ファイザー・インク |
ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
SG11201801024XA
(en)
|
2016-08-05 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Therapeutic or preventive compositions for il-8-related diseases
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
AU2017311585A1
(en)
|
2016-08-12 |
2019-02-28 |
Genentech, Inc. |
Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
|
SI3733712T1
(sl)
|
2016-08-15 |
2023-12-29 |
Novartis Ag |
Režimi in postopki zdravljenja multiple skleroze z uporabo ofatumumaba
|
SG11201901228QA
(en)
|
2016-08-15 |
2019-03-28 |
Genentech Inc |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
JP7022741B2
(ja)
|
2016-08-25 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
多機能化ケイ素ナノ粒子、その調製方法、及び電気化学発光に基づく検出方法におけるその使用
|
EP3503930A4
(en)
|
2016-08-29 |
2020-08-05 |
Fred Hutchinson Cancer Research Center |
CHELATING PLATFORM FOR DELIVERY OF RADIONUCLIDES
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
BR112019003989A2
(pt)
|
2016-09-06 |
2019-05-28 |
Chugai Pharmaceutical Co Ltd |
métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
|
JP7018210B2
(ja)
|
2016-09-06 |
2022-02-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ヒドロキシピリドネートアクチニド/ランタニド体外除去剤の製剤
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
EP3510398A1
(en)
|
2016-09-12 |
2019-07-17 |
Isoplexis Corporation |
System and methods for multiplexed analysis of cellular and other immunotherapeutics
|
IL265362B1
(en)
|
2016-09-14 |
2024-01-01 |
Merck Patent Gmbh |
Antibodies against C-MET and drug conjugates containing such antibodies
|
EP3512878B1
(en)
|
2016-09-15 |
2020-10-21 |
NovImmune SA |
Bispecific antibody display on phage surface
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
AU2017327828B2
(en)
|
2016-09-16 |
2023-11-16 |
Shanghai Henlius Biotech, Inc. |
Anti-PD-1 antibodies
|
EP3515950A4
(en)
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
NEW ANTI-PCSK9 ANTIBODIES
|
WO2018055031A1
(en)
|
2016-09-21 |
2018-03-29 |
Aarhus Universitet |
Acid-base transport inhibitors
|
WO2018055023A1
(en)
|
2016-09-22 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of lung cancer
|
EP4268845A3
(en)
|
2016-09-23 |
2024-02-28 |
F. Hoffmann-La Roche AG |
Uses of il-13 antagonists for treating atopic dermatitis
|
JP6929354B2
(ja)
|
2016-09-24 |
2021-09-01 |
アブビトロ, エルエルシー |
親和性−オリゴヌクレオチドコンジュゲートおよびその使用
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
US10858428B2
(en)
|
2016-09-28 |
2020-12-08 |
Xoma (Us) Llc |
Antibodies that bind interleukin-2 and uses thereof
|
WO2018064299A1
(en)
|
2016-09-29 |
2018-04-05 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
|
GB201616699D0
(en)
|
2016-09-30 |
2016-11-16 |
Mab Designs Ltd |
Antibodies
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
JP2019535015A
(ja)
|
2016-10-03 |
2019-12-05 |
アボット・ラボラトリーズAbbott Laboratories |
患者サンプルにおけるgfap状況を評価する改善された方法
|
JP2019537621A
(ja)
|
2016-10-04 |
2019-12-26 |
フェアバンクス ファーマシューティカルズ,インコーポレイテッド |
抗fstl3抗体およびその使用
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
IL265762B2
(en)
|
2016-10-06 |
2024-04-01 |
Merck Patent Gmbh |
Dosing regimen of avolumab for cancer treatment
|
CN110225927B
(zh)
|
2016-10-07 |
2024-01-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
JP6949468B2
(ja)
|
2016-10-17 |
2021-10-13 |
ルプレヒト−カールス−ウニベルジテート ハイデルベルク |
腫瘍抗原をコードする麻疹ウイルス
|
JP7128827B2
(ja)
|
2016-10-24 |
2022-08-31 |
エフ.ホフマン-ラ ロシュ アーゲー |
固定分析物
|
JP2019535306A
(ja)
|
2016-10-25 |
2019-12-12 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル) |
Cd160膜貫通型アイソフォームと結合するモノクローナル抗体
|
AU2017348365A1
(en)
|
2016-10-28 |
2019-05-23 |
Astute Medical, Inc. |
Use of antibodies to TIMP-2 for the improvement of renal function
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
US11617815B2
(en)
|
2016-10-31 |
2023-04-04 |
Sofregen Medical, Inc. |
Compositions comprising silk fibroin particles and uses thereof
|
DK3538891T3
(da)
|
2016-11-11 |
2022-03-28 |
Isoplexis Corp |
Sammensætninger og fremgangsmåder til samtidig genomisk, transkriptomisk og proteomisk analyse af enkeltceller
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
EP4353822A2
(en)
|
2016-11-17 |
2024-04-17 |
2seventy bio, Inc. |
Tgf beta signal convertor
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
KR20190077103A
(ko)
|
2016-11-21 |
2019-07-02 |
오비아이 파머 인코퍼레이티드 |
접합된 생물학적 분자, 제약 조성물 및 방법
|
CN109937034B
(zh)
|
2016-11-21 |
2022-09-16 |
济世-伊沃泰克生物制品有限公司 |
阿柏西普制剂及其用途
|
JP7080234B2
(ja)
|
2016-11-23 |
2022-06-03 |
トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー |
ベンズアミドおよび活性化合物組成物および使用方法
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
WO2018100190A1
(en)
|
2016-12-02 |
2018-06-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
KR20230146126A
(ko)
|
2016-12-07 |
2023-10-18 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CN110087668A
(zh)
|
2016-12-07 |
2019-08-02 |
Ra制药公司 |
补体活性的调节剂
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
CN110248668B
(zh)
|
2016-12-15 |
2023-05-30 |
杜克大学 |
用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
WO2018114748A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
CN108239150A
(zh)
|
2016-12-24 |
2018-07-03 |
信达生物制药(苏州)有限公司 |
抗pcsk9抗体及其用途
|
BR112019010915A2
(pt)
|
2016-12-27 |
2019-10-01 |
Hoffmann La Roche |
anticorpo monoclonal, métodos para medir um analito em uma amostra e para produzir um anticorpo, uso de um anticorpo, kit de teste de imunoensaio e imunógeno
|
EP3562842A1
(en)
|
2016-12-27 |
2019-11-06 |
H. Hoffnabb-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
KR102448439B1
(ko)
|
2016-12-27 |
2022-09-27 |
에프. 호프만-라 로슈 아게 |
신규한 비오틴-특이적 단일클론 항체 및 그 용도
|
WO2018122249A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
|
WO2018122245A1
(en)
|
2016-12-28 |
2018-07-05 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
WO2018129078A1
(en)
|
2017-01-04 |
2018-07-12 |
Research Institute At Nationwide Children's Hospital |
Dnabii vaccines and antibodies with enhanced activity
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
US11034667B2
(en)
|
2017-01-09 |
2021-06-15 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
EP3573995A1
(en)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
EP3577460B1
(en)
|
2017-02-02 |
2021-01-20 |
Roche Diagnostics GmbH |
Immunoassay using at least two pegylated analyte-specific binding agents
|
TW202339799A
(zh)
|
2017-02-03 |
2023-10-16 |
法商艾提寇生物技術公司 |
使用抗人類gpvi抗體抑制血小板凝集
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
EP3579872A1
(en)
|
2017-02-10 |
2019-12-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
US11685776B2
(en)
|
2017-03-02 |
2023-06-27 |
Novartis Ag |
Engineered heterodimeric proteins
|
MA47812A
(fr)
|
2017-03-03 |
2021-04-14 |
Seagen Inc |
Composés interagissant avec le glycane et méthodes d'utilisation
|
WO2018170145A1
(en)
|
2017-03-14 |
2018-09-20 |
Bioverativ Usa Inc. |
Methods for treating complement-mediated diseases and disorders
|
WO2018170178A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
CA3054955A1
(en)
|
2017-03-15 |
2018-09-20 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
EP4095161A1
(en)
|
2017-03-15 |
2022-11-30 |
Tsinghua University |
Novel anti-trkb antibodies
|
EP3600442A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
KR20200007776A
(ko)
|
2017-03-22 |
2020-01-22 |
제넨테크, 인크. |
히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
WO2018175994A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US20210186982A1
(en)
|
2017-03-24 |
2021-06-24 |
Universite Nice Sophia Antipolis |
Methods and compositions for treating melanoma
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
WO2018178029A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
WO2018178030A1
(en)
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
|
TW201900672A
(zh)
|
2017-03-27 |
2019-01-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之抗原結合受體型式
|
MX2019011526A
(es)
|
2017-03-27 |
2019-12-05 |
Hoffmann La Roche |
Receptores de union a antigeno mejorados.
|
SG10201911225WA
(en)
|
2017-03-28 |
2020-01-30 |
Genentech Inc |
Methods of treating neurodegenerative diseases
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
US20210275543A1
(en)
|
2017-03-30 |
2021-09-09 |
Nserm (Institut National De La Santé Et De La Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
CN110494161A
(zh)
|
2017-03-30 |
2019-11-22 |
默克专利股份有限公司 |
用于治疗癌症的抗pd-l1抗体和dna-pk抑制剂的组合
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
TW201836636A
(zh)
|
2017-03-31 |
2018-10-16 |
公立大學法人奈良縣立醫科大學 |
含有替代凝血因子viii功能之多特異性抗原結合分子之用於預防和/或治療凝血因子ix異常症的醫藥組合物
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
ES2955852T3
(es)
|
2017-04-03 |
2023-12-07 |
Hoffmann La Roche |
Anticuerpos de unión a STEAP-1
|
MX2019011770A
(es)
|
2017-04-03 |
2020-01-09 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
|
RU2766234C2
(ru)
|
2017-04-04 |
2022-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
|
SI3606954T1
(sl)
|
2017-04-05 |
2022-10-28 |
F. Hoffmann - La Roche Ag |
Protitelesa proti LAG3
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
CN110475779A
(zh)
|
2017-04-12 |
2019-11-19 |
豪夫迈·罗氏有限公司 |
标记含醛靶分子的方法
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
KR20190140454A
(ko)
|
2017-04-13 |
2019-12-19 |
아두로 바이오테크 홀딩스, 유럽 비.브이. |
항-sirp 알파 항체
|
CA3058541A1
(en)
|
2017-04-14 |
2018-10-18 |
Gamamabs Pharma |
Amhrii-binding compounds for preventing or treating lung cancers
|
CN110891970A
(zh)
|
2017-04-14 |
2020-03-17 |
加马玛布斯制药公司 |
用于预防或治疗癌症的amhrii结合化合物
|
US10877048B2
(en)
|
2017-04-15 |
2020-12-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
US11866506B2
(en)
|
2017-04-21 |
2024-01-09 |
Mellitus, Llc |
Anti-CD59 antibodies
|
SG11201909048TA
(en)
|
2017-04-21 |
2019-11-28 |
Genentech Inc |
Use of klk5 antagonists for treatment of a disease
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
KR20200012860A
(ko)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
CN110799541A
(zh)
|
2017-04-27 |
2020-02-14 |
特沙诺有限公司 |
针对淋巴细胞活化基因-3(lag-3)的抗体药剂及其用途
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
CN110832070A
(zh)
|
2017-05-10 |
2020-02-21 |
艾欧凡斯生物治疗公司 |
液体肿瘤来源肿瘤浸润淋巴细胞的扩增及其治疗用途
|
GB201707561D0
(en)
|
2017-05-11 |
2017-06-28 |
Argenx Bvba |
GARP-TGF-beta antibodies
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
EP3631012B1
(en)
|
2017-05-26 |
2022-06-08 |
AbVitro LLC |
High-throughput polynucleotide library sequencing and transcriptome analysis
|
BR112019025313A2
(pt)
|
2017-05-30 |
2020-06-23 |
Abbott Laboratories |
Métodos para auxílio no diagnóstico e avaliação de uma lesão cerebral traumática leve em um indivíduo humano usando troponina cardíaca i
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
WO2018224441A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
WO2018224439A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-hsa antibodies
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
EP3641802A1
(en)
|
2017-06-22 |
2020-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗tim−3抗体のための投与レジメンおよびその使用
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
US20200123621A1
(en)
|
2017-06-27 |
2020-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identifying and treating resistance to ctla4 antagonists in leukemia
|
WO2019002548A1
(en)
|
2017-06-29 |
2019-01-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
|
CA3068041A1
(en)
|
2017-07-03 |
2019-01-10 |
Abbott Laboratories |
Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
|
WO2019010299A1
(en)
|
2017-07-06 |
2019-01-10 |
Memorial Sloan Kettering Cancer Center |
DOTA-HAPTENE COMPOSITIONS FOR RADIOIMMUNOTHERAPY PRECIBLED BY A BISPECIFIC ANTIGEN ANTI-DOTA / ANTI-TUMOR ANTIBODY
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
EP3652540A4
(en)
|
2017-07-12 |
2021-04-07 |
The Johns Hopkins University |
PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
AU2018302283A1
(en)
|
2017-07-20 |
2020-02-06 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
WO2019018729A1
(en)
|
2017-07-20 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR IDENTIFICATION AND TREATMENT OF NEUROENDOCRINE METASTATIC TUMORS OF INTESTINAL HAIL
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
EP3658173A1
(en)
|
2017-07-25 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
WO2019020807A1
(en)
|
2017-07-28 |
2019-01-31 |
Gene Signal International Sa |
CD9P-1 TARGETING ANTIBODIES AND USES THEREOF
|
WO2019023525A1
(en)
|
2017-07-28 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTION MODULATORS
|
CN110869050A
(zh)
|
2017-07-28 |
2020-03-06 |
豪夫迈·罗氏有限公司 |
双特异性抗体配制剂
|
EP3589658A1
(en)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
MD3601358T2
(ro)
|
2017-08-03 |
2023-10-31 |
Alector Llc |
Anticorpi anti-TREM2 și metode de utilizare a acestora
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
EP3459968A1
(en)
|
2017-09-20 |
2019-03-27 |
Numab Innovation AG |
Novel stable antibody variable domain framework combinations
|
BR112020005519A2
(pt)
|
2017-09-20 |
2020-10-27 |
The University Of British Columbia |
novos anticorpos anti-hla-a2 e usos dos mesmos
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Pd-1系結合アンタゴニストおよびgpc3標的化剤を使用する併用療法のための投与レジメン
|
US20200268837A1
(en)
|
2017-09-20 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating autophagy
|
EP3459970A1
(en)
|
2017-09-20 |
2019-03-27 |
Universität Heidelberg |
Norovirus nanobodies
|
EP3688007A1
(en)
|
2017-09-27 |
2020-08-05 |
The University of York |
Bioconjugation of polypeptides
|
AU2018338859A1
(en)
|
2017-09-29 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
CN117430699A
(zh)
|
2017-09-30 |
2024-01-23 |
合肥立方制药股份有限公司 |
结合至纤维连接蛋白b结构域的蛋白
|
CN111447934A
(zh)
|
2017-10-06 |
2020-07-24 |
4阵营疗法公司 |
用于治疗尿素循环障碍的方法和组合物,尤其是otc缺乏症
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
WO2019072870A1
(en)
|
2017-10-10 |
2019-04-18 |
Numab Innovation Ag |
ANTIBODIES TARGETING CD137 AND METHODS OF USE
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
EP3470428A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Antibodies targeting cd137 and methods of use thereof
|
MX2020003562A
(es)
|
2017-10-10 |
2020-10-01 |
Numab Therapeutics AG |
Anticuerpo multiespecifico.
|
EP3470429A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Innovation AG |
Antibodies targeting pdl1 and methods of use thereof
|
CN111225926A
(zh)
|
2017-10-10 |
2020-06-02 |
努玛治疗有限公司 |
靶向pdl1的抗体及其使用方法
|
CA3078974A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
WO2019077092A1
(en)
|
2017-10-20 |
2019-04-25 |
F. Hoffmann-La Roche Ag |
METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
|
JP7438942B2
(ja)
|
2017-10-30 |
2024-02-27 |
エフ. ホフマン-ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
EP3703821A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Bispecific 2+1 contorsbodies
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
CA3082365A1
(en)
|
2017-11-09 |
2019-05-16 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
MX2020004933A
(es)
|
2017-11-14 |
2021-01-08 |
Arcellx Inc |
Polipéptidos que contienen dominios d y sus usos.
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
SG11202004426SA
(en)
|
2017-11-17 |
2020-06-29 |
Merck Sharp & Dohme |
Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
|
CN111356471A
(zh)
|
2017-11-20 |
2020-06-30 |
济世发展生物药业有限公司 |
包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
WO2019102456A1
(en)
|
2017-11-27 |
2019-05-31 |
University Of Rijeka Faculty Of Medicine |
Immunotoxins for treating cancer
|
WO2019113506A1
(en)
|
2017-12-07 |
2019-06-13 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
CA3067055A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
|
CN111094983A
(zh)
|
2017-12-09 |
2020-05-01 |
雅培实验室 |
使用胶质细胞原纤维酸性蛋白(gfap)和/或泛素羧基末端水解酶l1(uch-l1)帮助诊断和评价已遭受骨科损伤并已遭受或可能已遭受头部损伤诸如轻度创伤性脑损伤(tbi)的患者的方法
|
JP2021506817A
(ja)
|
2017-12-14 |
2021-02-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療するための投与計画におけるcea cd3二重特異性抗体及びpd−1軸結合アンタゴニストの使用
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
AU2018388791A1
(en)
|
2017-12-19 |
2020-07-16 |
The Rockefeller University |
Human IgG Fc domain variants with improved effector function
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
CN111492243A
(zh)
|
2017-12-21 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的car-t细胞测定法
|
JP7394058B2
(ja)
|
2017-12-21 |
2023-12-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
EP3732202A4
(en)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
|
KR20200104886A
(ko)
|
2017-12-28 |
2020-09-04 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
BR112020010430A2
(pt)
|
2017-12-29 |
2020-11-24 |
Abbott Laboratories |
biomarcadores e métodos inovadores para diagnosticar e avaliar lesão cerebral traumática
|
JP7436365B2
(ja)
|
2017-12-29 |
2024-02-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
抗vegf抗体及び使用の方法
|
CN108218990B
(zh)
|
2017-12-29 |
2021-03-02 |
南京优迈生物科技有限公司 |
分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
WO2019137541A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
US20210054064A1
(en)
|
2018-01-24 |
2021-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injusry in an organ
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
安定化された免疫グロブリンドメイン
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
CA3081125A1
(en)
|
2018-02-01 |
2019-08-08 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully humanized anti-b cell maturation antigen (bcma) single-chain antibody and use thereof
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CA3226165A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
WO2019164979A1
(en)
|
2018-02-21 |
2019-08-29 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
US20200399376A1
(en)
|
2018-02-26 |
2020-12-24 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3092470A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
EP3759491A1
(en)
|
2018-03-01 |
2021-01-06 |
H. Hoffnabb-La Roche Ag |
Specificity assay for novel target antigen binding moieties
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
AU2019236372A1
(en)
|
2018-03-13 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
EP3765524A4
(en)
|
2018-03-14 |
2021-12-22 |
Surface Oncology, Inc. |
Antibodies for binding CD39 and uses thereof
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
KR20200135510A
(ko)
|
2018-03-29 |
2020-12-02 |
제넨테크, 인크. |
포유류 세포들에서 젖분비자극 활성의 조절
|
CN111886254B
(zh)
|
2018-03-30 |
2023-12-08 |
南京传奇生物科技有限公司 |
针对lag-3的单结构域抗体及其用途
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
CN112424601A
(zh)
|
2018-04-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
检测癌症患者中肿瘤抗原的诊断性测定法
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
WO2019197600A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
SG11202010116PA
(en)
|
2018-04-13 |
2020-11-27 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
MX2020010729A
(es)
|
2018-04-13 |
2021-03-09 |
Genentech Inc |
Formulaciones de inmunoconjugado anti-cd79b estables.
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
TW202014201A
(zh)
|
2018-05-04 |
2020-04-16 |
德商馬克專利公司 |
用於治療癌症之PD-1/PD-L1,TGFβ及DNA-PK之組合抑制
|
WO2019213619A1
(en)
|
2018-05-04 |
2019-11-07 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
EP3790904A1
(en)
|
2018-05-08 |
2021-03-17 |
Amgen Inc. |
Bispecific antibodies with cleavable c-terminal charge-paired tags
|
JP2021522801A
(ja)
|
2018-05-09 |
2021-09-02 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
ヒトネクチン4に特異的な抗体
|
WO2019217913A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
CN112166196A
(zh)
|
2018-05-18 |
2021-01-01 |
豪夫迈·罗氏有限公司 |
大核酸的靶向细胞内递送
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
WO2019224715A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
UA128113C2
(uk)
|
2018-05-25 |
2024-04-10 |
ЕЛЕКТОР ЕлЕлСі |
Анти-sirpa антитіла і способи їхнього застосування
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
JP7360401B2
(ja)
|
2018-05-31 |
2023-10-12 |
グリコネックス インコーポレイテッド |
バイアンテナ型ルイスbおよびルイスy抗原に結合する治療抗体
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
EP3805400A4
(en)
|
2018-06-04 |
2022-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
WO2019236965A1
(en)
|
2018-06-08 |
2019-12-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
WO2019233842A1
(en)
|
2018-06-08 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Peptidic linker with reduced post-translational modification
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
EP3806903B1
(en)
|
2018-06-14 |
2024-02-14 |
2seventy bio, Inc. |
Cd79a chimeric antigen receptors
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
BR112020026384A2
(pt)
|
2018-06-23 |
2021-03-30 |
Genentech, Inc. |
Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
CA3099176A1
(en)
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
PE20211805A1
(es)
|
2018-06-29 |
2021-09-14 |
Incyte Corp |
Formulaciones de un inhibidor de axl/mer
|
AU2019297324B9
(en)
|
2018-07-03 |
2022-07-07 |
Gilead Sciences, Inc. |
Antibodies that target HIV gp120 and methods of use
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
SG11202100160SA
(en)
|
2018-07-11 |
2021-02-25 |
Celgene Corp |
Uses of anti-bcma chimeric antigen receptors
|
LT3618928T
(lt)
|
2018-07-13 |
2023-04-11 |
Alector Llc |
Anti-sortilino antikūnai ir jų panaudojimo būdai
|
GB201811597D0
(en)
|
2018-07-16 |
2018-08-29 |
Hemogad Tech Ltd |
Analyser
|
CA3104147A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
BR112021000727A2
(pt)
|
2018-07-20 |
2021-04-13 |
Surface Oncology, Inc. |
Composições anti-cd112r e métodos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
WO2020021061A1
(en)
|
2018-07-26 |
2020-01-30 |
Pieris Pharmaceuticals Gmbh |
Humanized anti-pd-1 antibodies and uses thereof
|
EP3830123A1
(en)
|
2018-07-27 |
2021-06-09 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
MD3830120T3
(ro)
|
2018-07-31 |
2023-11-30 |
Pieris Pharmaceuticals Gmbh |
Noi proteine de fuziune specifice pentru CD137 și PD-L1
|
JPWO2020027330A1
(ja)
|
2018-08-03 |
2021-08-19 |
中外製薬株式会社 |
互いに連結された2つの抗原結合ドメインを含む抗原結合分子
|
BR112021002130A2
(pt)
|
2018-08-08 |
2021-05-04 |
Genentech, Inc. |
formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
|
CA3109253A1
(en)
|
2018-08-10 |
2020-02-13 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
SG10202106830VA
(en)
|
2018-08-10 |
2021-08-30 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
WO2020037174A1
(en)
|
2018-08-16 |
2020-02-20 |
The Johns Hopkins University |
Antibodies to human znt8
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
CA3106881A1
(en)
|
2018-08-27 |
2020-03-05 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
AU2019336426A1
(en)
|
2018-09-04 |
2021-04-29 |
Nanjing Umab-Biopharma Co., Ltd. |
Fusion protein and its application in preparing medicine for treating tumor and/or viral infection
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
JP2022501038A
(ja)
|
2018-09-20 |
2022-01-06 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
凍結保存腫瘍サンプルからのtilの拡大培養
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
WO2020064702A1
(en)
|
2018-09-25 |
2020-04-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
MX2021003548A
(es)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
|
WO2020070240A1
(en)
|
2018-10-04 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
|
JP2022512580A
(ja)
|
2018-10-05 |
2022-02-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
細菌バイオフィルムの酵素的破壊のための組成物および方法
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
EP3636320A1
(en)
|
2018-10-09 |
2020-04-15 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
WO2020074584A1
(en)
|
2018-10-09 |
2020-04-16 |
Numab Therapeutics AG |
Antibodies targeting cd137 and methods of use thereof
|
WO2020074937A1
(en)
|
2018-10-09 |
2020-04-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
CN113056287A
(zh)
|
2018-10-24 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
缀合的化学降解诱导剂及使用方法
|
WO2020087107A1
(en)
|
2018-10-31 |
2020-05-07 |
The University Of Sydney |
Compositions and methods for treating viral infections
|
EP3877407A1
(en)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Methods of producing two chain proteins in prokaryotic host cells
|
WO2020096989A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
GB201818618D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against ambra-1
|
GB201818622D0
(en)
|
2018-11-15 |
2019-01-02 |
Amlo Biosciences Ltd |
Monoclonal antibodies against loricrin
|
WO2020099533A1
(en)
|
2018-11-16 |
2020-05-22 |
F. Hoffmann-La Roche Ag |
Streptavidin-coated solid phases with a member of a binding pair
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
TW202038959A
(zh)
|
2018-12-20 |
2020-11-01 |
瑞士商諾華公司 |
Mdm2抑制劑之新型給藥方案
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
CA3121804A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストcd28抗原結合分子
|
CA3120474A1
(en)
|
2018-12-21 |
2020-06-25 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
CR20210325A
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
CN113286821A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的激动性cd28抗原结合分子
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
AU2020205150A1
(en)
|
2019-01-03 |
2021-07-22 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
CA3125762A1
(en)
|
2019-01-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
AU2020207664A1
(en)
|
2019-01-13 |
2021-07-22 |
University Of Rijeka Faculty Of Medicine |
Antibodies specific to human Nectin-2
|
TW202043272A
(zh)
|
2019-01-14 |
2020-12-01 |
美商建南德克公司 |
使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
AU2020216295A1
(en)
|
2019-01-28 |
2021-09-09 |
Maple Biotech Llc |
PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
CN116063520A
(zh)
|
2019-01-30 |
2023-05-05 |
真和制药有限公司 |
抗gal3抗体及其用途
|
KR20210122243A
(ko)
|
2019-01-31 |
2021-10-08 |
누맙 세러퓨틱스 아게 |
TNFα 및 IL-17A에 대한 특이성을 가지는 다중 특이적 항체, IL-17A를 표적화하는 항체, 그리고 이의 사용 방법
|
EP3689907A1
(en)
|
2019-01-31 |
2020-08-05 |
Numab Therapeutics AG |
Antibodies targeting il-17a and methods of use thereof
|
WO2020161083A1
(en)
|
2019-02-04 |
2020-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
CN113396230A
(zh)
|
2019-02-08 |
2021-09-14 |
豪夫迈·罗氏有限公司 |
癌症的诊断和治疗方法
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
JP2022520811A
(ja)
|
2019-02-15 |
2022-04-01 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
WO2020168059A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Claudin 6 antibodies and uses thereof
|
WO2020168315A1
(en)
|
2019-02-15 |
2020-08-20 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
CN113661175A
(zh)
|
2019-02-15 |
2021-11-16 |
整体分子公司 |
包含共同轻链的抗体及其用途
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
US20220153864A1
(en)
|
2019-02-26 |
2022-05-19 |
Pieris Pharmaceuticals Gmbh |
Novel Fusion Proteins Specific for CD137 and GPC3
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
MX2021010288A
(es)
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores a partir de tumores liquidos y usos terapeuticos de los mismos.
|
SG11202108011UA
(en)
|
2019-03-01 |
2021-08-30 |
Allogene Therapeutics Inc |
Dll3 targeting chimeric antigen receptors and binding agents
|
WO2020178313A1
(en)
|
2019-03-05 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New biomarkers and biotargets in renal cell carcinoma
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220143148A1
(en)
|
2019-03-14 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
|
TW202100556A
(zh)
|
2019-03-14 |
2021-01-01 |
美商建南德克公司 |
使用her2 t細胞依賴性雙特異性抗體之治療
|
WO2020191069A1
(en)
|
2019-03-18 |
2020-09-24 |
The Broad Institute, Inc. |
Modulation of type 2 immunity by targeting clec-2 signaling
|
CA3132420A1
(en)
|
2019-03-18 |
2020-09-24 |
Deutsches Krebsforschungszentrum |
Expression constructs for the genetic modification of cells
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
WO2020193441A1
(en)
|
2019-03-22 |
2020-10-01 |
Université de Paris |
New inhibitors of lrrk2/pp1 interaction
|
WO2020194317A1
(en)
|
2019-03-28 |
2020-10-01 |
Yeda Research And Development Co. Ltd. |
Method of treating lipid-related disorders
|
MA55519A
(fr)
|
2019-03-29 |
2022-02-09 |
Atarga Llc |
Anticorps anti-fgf23
|
EP3946417A1
(en)
|
2019-03-29 |
2022-02-09 |
Pieris Pharmaceuticals GmbH |
Inhaled administration of lipocalin muteins
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
CN113660953A
(zh)
|
2019-04-01 |
2021-11-16 |
豪夫迈·罗氏有限公司 |
用于稳定含蛋白质制剂的组合物和方法
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
JP2022527860A
(ja)
|
2019-04-02 |
2022-06-06 |
ケンジョッケティ バイオテクノロジー,インク. |
排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
|
WO2020201442A1
(en)
|
2019-04-03 |
2020-10-08 |
Orega Biotech |
Combination therapies based on pd1 and il-17b inhibitors
|
CA3136488A1
(en)
|
2019-04-08 |
2020-10-15 |
Biogen Ma Inc. |
Anti-integrin antibodies and uses thereof
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
JP2022527565A
(ja)
|
2019-04-12 |
2022-06-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CEA CD3二重特異性抗体及びWntシグナル伝達阻害剤を使用するがんの治療
|
EP3956664A1
(en)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
WO2020214995A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
GB201906297D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Biomarkers for disease progression in squamous cell carcinoma
|
EP3962947A2
(en)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with an anti-pd-l1 antibody
|
SG11202111938YA
(en)
|
2019-05-03 |
2021-11-29 |
Genentech Inc |
Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
|
GB201906302D0
(en)
|
2019-05-03 |
2019-06-19 |
Amlo Biosciences Ltd |
Methods of determining the margin of a tumour
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
US20220409734A1
(en)
|
2019-05-10 |
2022-12-29 |
Yutaka Nishimoto |
Antibody drug conjugates
|
AU2020275415A1
(en)
|
2019-05-14 |
2021-11-25 |
Genentech, Inc. |
Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
|
JP2022538733A
(ja)
|
2019-05-20 |
2022-09-06 |
インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) |
新規抗cd25抗体
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
CA3140142A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
EP3976090A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
US20230053328A9
(en)
|
2019-05-24 |
2023-02-16 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
CN114599675A
(zh)
|
2019-05-28 |
2022-06-07 |
上海科技大学 |
用于治疗clouston型外胚层发育不良2的组合物和方法
|
CN114174344A
(zh)
|
2019-05-30 |
2022-03-11 |
美国安进公司 |
工程改造铰链区以驱动抗体二聚化
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
CA3142635A1
(en)
|
2019-06-04 |
2020-12-10 |
Biotheus Inc. |
Anti-ceacam5 monoclonal antibody and preparation method thereof and use thereof
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
US20220253669A1
(en)
|
2019-06-07 |
2022-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Information processing system, information processing method, program, and method for producing antigen-binding molecule or protein
|
KR20220031616A
(ko)
|
2019-06-11 |
2022-03-11 |
알렉터 엘엘씨 |
치료요법에 사용하기 위한 항-소르틸린 항체
|
AU2020304813A1
(en)
|
2019-06-26 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding CEA and 4-1BBL
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2020264384A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
BR112021026890A2
(pt)
|
2019-07-08 |
2022-03-15 |
Res Inst Nationwide Childrens Hospital |
Composições de anticorpo para interromper biofilmes
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
WO2021009187A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies against canine ctla-4
|
EP3999540A1
(en)
|
2019-07-16 |
2022-05-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antibodies having specificity for cd38 and uses thereof
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
KR20220058540A
(ko)
|
2019-07-31 |
2022-05-09 |
알렉터 엘엘씨 |
항-ms4a4a 항체 및 이의 사용 방법
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
KR20220044527A
(ko)
|
2019-08-01 |
2022-04-08 |
인사이트 코포레이션 |
Ido 억제제의 투여 요법
|
CN114401743A
(zh)
|
2019-08-02 |
2022-04-26 |
法国国家健康和医学研究院 |
中和颗粒酶b用于向经历过心肌梗塞的受试者提供心脏保护
|
GB201911210D0
(en)
|
2019-08-06 |
2019-09-18 |
Amlo Biosciences Ltd |
Clinical management of oropharyngeal squamous cell carcinoma
|
WO2021030303A1
(en)
|
2019-08-12 |
2021-02-18 |
Voyager Therapeutics, Inc. |
High-sensitivity immunoassay for the detection of frataxin in biofluids
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
TW202118512A
(zh)
|
2019-09-12 |
2021-05-16 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
BR112022002351A2
(pt)
|
2019-09-16 |
2022-07-19 |
Surface Oncology Inc |
Composições e métodos de anticorpo anti-cd39
|
BR112022004972A2
(pt)
|
2019-09-18 |
2022-06-28 |
Genentech Inc |
Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
|
US20220348687A1
(en)
|
2019-09-20 |
2022-11-03 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing Genscript Biotech Co Ltd |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
JP2022548978A
(ja)
|
2019-09-27 |
2022-11-22 |
ジェネンテック, インコーポレイテッド |
薬抗tigit及び抗pd-l1アンタゴニスト抗体を用いた処置のための投薬
|
CA3155930A1
(en)
|
2019-09-27 |
2021-04-01 |
Starkage Therapeutics |
SENESCENT CELL-ASSOCIATED ANTIGEN-BINDING DOMAINS, ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS COMPRISING THEM, AND USES THEREOF
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
GB201914399D0
(en)
|
2019-10-04 |
2019-11-20 |
Univ Newcastle |
Biomarkers for assessing explant organ viability
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
KR20220079590A
(ko)
|
2019-10-04 |
2022-06-13 |
티에이이 라이프 사이언시스 |
Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
WO2021076798A1
(en)
|
2019-10-15 |
2021-04-22 |
Sofregen Medical, Inc. |
Delivery devices for delivering and methods of delivering compositions
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
EP3812008A1
(en)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-competitive antagonist antibody
|
JP2023502876A
(ja)
|
2019-11-04 |
2023-01-26 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
がんの治療のためのher2/4-1bb二重特異性融合タンパク質
|
EP3816185A1
(en)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispecific antibody directed against pd-l1 and a tumor-associated antigen
|
BR112022004998A2
(pt)
|
2019-11-05 |
2022-06-14 |
Merck Patent Gmbh |
Anticorpos anti-tigit e usos dos mesmos
|
CA3160178A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Uses of anti-bcma chimeric antigen receptors
|
KR20220093323A
(ko)
|
2019-11-05 |
2022-07-05 |
에프. 호프만-라 로슈 아게 |
HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
|
MX2022005400A
(es)
|
2019-11-06 |
2022-05-24 |
Genentech Inc |
Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
JP2023503429A
(ja)
|
2019-11-22 |
2023-01-30 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる、急性骨髄性白血病の処置のための、アドレノメデュリン阻害剤
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
KR20220110537A
(ko)
|
2019-12-05 |
2022-08-08 |
알렉터 엘엘씨 |
항-trem2 항체 사용 방법
|
WO2021118930A2
(en)
|
2019-12-09 |
2021-06-17 |
Genentech, Inc. |
Anti-pd-l1 antibody formulations
|
GB201918103D0
(en)
|
2019-12-10 |
2020-01-22 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
WO2021116277A1
(en)
|
2019-12-10 |
2021-06-17 |
Institut Pasteur |
New antibody blocking human fcgriiia and fcgriiib
|
EP4073119A1
(en)
|
2019-12-12 |
2022-10-19 |
Alector LLC |
Methods of use of anti-cd33 antibodies
|
CR20220329A
(es)
|
2019-12-13 |
2022-11-23 |
Alector Llc |
Anticuerpos anti–mertk y metodos de uso de los mismos
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
JP7296467B2
(ja)
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hla-a2/mage-a4に結合する抗体
|
WO2021123902A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
MX2022007746A
(es)
|
2019-12-23 |
2022-10-07 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso.
|
CR20220357A
(es)
|
2019-12-27 |
2022-08-24 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
WO2021138498A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
IL294436A
(en)
|
2020-01-03 |
2022-09-01 |
Incyte Corp |
Anti-cd73 antibodies and their uses
|
TW202135824A
(zh)
|
2020-01-03 |
2021-10-01 |
美商英塞特公司 |
包含a2a/a2b及pd-1/pd-l1抑制劑之組合療法
|
IL292780A
(en)
|
2020-01-09 |
2022-07-01 |
Hoffmann La Roche |
A new 4-1bbl trimer containing antigen-binding molecules
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2021144426A1
(en)
|
2020-01-17 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202142230A
(zh)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
用於以抗tigit拮抗體抗體治療癌症之方法
|
WO2021155028A1
(en)
|
2020-01-29 |
2021-08-05 |
Kenjockety Biotechnology, Inc. |
Anti-mdr1 antibodies and uses thereof
|
CN116650628A
(zh)
|
2020-01-31 |
2023-08-29 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
CA3167349A1
(en)
|
2020-02-10 |
2021-08-19 |
Qing Zhou |
Claudin 18.2 antibody and use thereof
|
KR20220139357A
(ko)
|
2020-02-10 |
2022-10-14 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
Cldn18.2 항체 및 그의 사용
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
EP4106767A1
(en)
|
2020-02-21 |
2022-12-28 |
Université de Liège |
Depletion of ext1 expression and/or activity improves cellular production of biological entities
|
WO2021170684A1
(en)
|
2020-02-24 |
2021-09-02 |
Oblique Therapeutics Ab |
Kras epitopes and antibodies
|
CN115427554A
(zh)
|
2020-02-24 |
2022-12-02 |
伊玛提克斯美国公司 |
扩增t细胞治疗癌症和相关恶性肿瘤的方法
|
US20230159637A1
(en)
|
2020-02-24 |
2023-05-25 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20210275666A1
(en)
|
2020-03-06 |
2021-09-09 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
KR20220156575A
(ko)
|
2020-03-19 |
2022-11-25 |
제넨테크, 인크. |
동종형 선택적 항-tgf-베타 항체 및 이용 방법
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
CN115916823A
(zh)
|
2020-03-20 |
2023-04-04 |
法国国家健康和医学研究院 |
人cd45rc特异的嵌合抗原受体及其用途
|
CA3169967A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
CN116075525A
(zh)
|
2020-03-31 |
2023-05-05 |
艾莱克特有限责任公司 |
抗mertk抗体及其使用方法
|
CN113461817A
(zh)
|
2020-03-31 |
2021-10-01 |
苏州泽璟生物制药股份有限公司 |
一种抗人cd47抗体及其抗原结合片段、制备方法和应用
|
AU2021250381A1
(en)
|
2020-03-31 |
2022-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing multispecific antigen-binding molecules
|
WO2021202235A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
WO2021198511A1
(en)
|
2020-04-03 |
2021-10-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of sars-cov-2 infection
|
MX2022012182A
(es)
|
2020-04-03 |
2022-12-08 |
Alector Llc |
Metodos de uso de anticuerpos anti-trem2.
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
BR112022020232A2
(pt)
|
2020-04-06 |
2022-12-13 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções
|
US20230132275A1
(en)
|
2020-04-08 |
2023-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
EP4136459A1
(en)
|
2020-04-13 |
2023-02-22 |
Abbott Laboratories |
Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
US20230149360A1
(en)
|
2020-04-21 |
2023-05-18 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the prevention and/or the treatment of spleen disorders
|
WO2021214129A1
(en)
|
2020-04-21 |
2021-10-28 |
Université Catholique de Louvain |
Alpha-2 adrenergic receptor agonists for the treatment of cancer
|
WO2021214258A1
(en)
|
2020-04-22 |
2021-10-28 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
JP2023523145A
(ja)
|
2020-04-27 |
2023-06-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
リポ蛋白(a)に対するイソ型非依存性抗体
|
WO2021222935A2
(en)
|
2020-04-28 |
2021-11-04 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
EP4143227A2
(en)
|
2020-04-30 |
2023-03-08 |
Sairopa B.V. |
Anti-cd103 antibodies
|
EP4146283A1
(en)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
WO2021229103A2
(en)
|
2020-05-15 |
2021-11-18 |
Apogenix Ag |
Multi-specific immune modulators
|
GB202007312D0
(en)
|
2020-05-18 |
2020-07-01 |
Synthetic Vac Ltd |
Mimotope peptides of the spike protein from the sars-cov-2 virus
|
EP4157881A1
(en)
|
2020-05-27 |
2023-04-05 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
EP4157461A1
(en)
|
2020-05-29 |
2023-04-05 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
EP3915580A1
(en)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispecific antibody
|
MX2022015157A
(es)
|
2020-06-02 |
2023-01-16 |
Arcus Biosciences Inc |
Anticuerpos para tigit.
|
WO2021247426A1
(en)
|
2020-06-04 |
2021-12-09 |
Kenjockety Biotechnology, Inc. |
Anti-abcg2 antibodies and uses thereof
|
CN116529267A
(zh)
|
2020-06-04 |
2023-08-01 |
肯乔克蒂生物技术股份有限公司 |
Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
|
JP2023527578A
(ja)
|
2020-06-05 |
2023-06-29 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
眼疾患を処置するための方法及び医薬組成物
|
WO2021245240A1
(en)
|
2020-06-05 |
2021-12-09 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
CR20220659A
(es)
|
2020-06-08 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso
|
GB202008651D0
(en)
|
2020-06-09 |
2020-07-22 |
Univ Newcastle |
Method of identifying complement modulators
|
IL298878A
(en)
|
2020-06-11 |
2023-02-01 |
Genentech Inc |
Nanolipoprotein-polypeptide conjugates and compositions, systems and methods using them
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
TWI811703B
(zh)
|
2020-06-19 |
2023-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與cd3及cd19結合之抗體
|
EP4168456A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
EP4168446A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and folr1
|
WO2021255137A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific antibodies
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
CN113912706A
(zh)
|
2020-07-09 |
2022-01-11 |
北京凯因科技股份有限公司 |
结合乙型肝炎病毒表面抗原的抗体及其应用
|
CA3188000A1
(en)
|
2020-07-13 |
2022-01-20 |
Genentech, Inc. |
Cell-based methods for predicting polypeptide immunogenicity
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
US20230303682A1
(en)
|
2020-07-17 |
2023-09-28 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Methods of Use
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
EP4189395A1
(en)
|
2020-07-28 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for preventing and treating a cancer
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
CN116419747A
(zh)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
靶向cd46的免疫偶联物及其使用方法
|
WO2022031948A1
(en)
|
2020-08-07 |
2022-02-10 |
Genentech, Inc. |
T cell-based methods for predicting polypeptide immunogenicity
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
EP4200338A1
(en)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
TW202227616A
(zh)
|
2020-08-21 |
2022-07-16 |
美商英麥提克斯股份有限公司 |
分離cd8+選擇t細胞的方法
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之CRISPR/Cas9多重剔除
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
JP2023539279A
(ja)
|
2020-08-31 |
2023-09-13 |
ジェネンテック, インコーポレイテッド |
抗体を産生するための方法
|
WO2022049061A1
(en)
|
2020-09-01 |
2022-03-10 |
Merck Patent Gmbh |
Nkp30 binders
|
EP4208483A1
(en)
|
2020-09-02 |
2023-07-12 |
Kenjockety Biotechnology, Inc. |
Anti-abcc1 antibodies and uses thereof
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Il1rapに結合する抗体及びその使用
|
EP3970752A1
(en)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Molecules with solubility tag and related methods
|
JP2023541482A
(ja)
|
2020-09-18 |
2023-10-02 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
バイオマーカー法および使用法
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
BR112023005399A2
(pt)
|
2020-09-24 |
2023-04-25 |
Hoffmann La Roche |
Anticorpo biespecífico, uso de um anticorpo biespecífico, métodos para tratamento de uma doença em um indivíduo e para prevenir ou mitigar um efeito adverso, inibidor de tirosina quinase, uso de um inibidor de tirosina quinase e invenção
|
WO2022064049A1
(en)
|
2020-09-28 |
2022-03-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for diagnosing brucella infection
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
CA3197047A1
(en)
|
2020-10-07 |
2022-04-14 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
EP3981789A1
(en)
|
2020-10-12 |
2022-04-13 |
Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives |
Anti-lilrb antibodies and uses thereof
|
US11440952B2
(en)
|
2020-10-16 |
2022-09-13 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
JP2023545566A
(ja)
|
2020-10-20 |
2023-10-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法
|
WO2022084300A1
(en)
|
2020-10-20 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosis and monitoring form of coronavirus infection
|
EP3988568A1
(en)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
WO2022090439A1
(en)
|
2020-10-30 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A TGFβ SIGNALING INHIBITOR
|
WO2022094116A1
(en)
|
2020-10-30 |
2022-05-05 |
Genentech, Inc. |
Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate
|
US20230416816A1
(en)
|
2020-11-03 |
2023-12-28 |
IsoPlexis Corporation |
Methods and devices for mulitplexed proteomic and genetic analysis and on-device preparation of cdna
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
IL302217A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
|
EP4240367A2
(en)
|
2020-11-04 |
2023-09-13 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
US20230398149A1
(en)
|
2020-11-04 |
2023-12-14 |
Celgene Corporation |
Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
WO2022096547A1
(en)
|
2020-11-05 |
2022-05-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-6 inhibitors for the treatment of acute chest syndrome in patients suffering from sickle cell disease
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
EP4240488A1
(en)
|
2020-11-09 |
2023-09-13 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
KR20230107235A
(ko)
|
2020-11-10 |
2023-07-14 |
에프. 호프만-라 로슈 아게 |
T 세포 관여제 관련 부정적인 효과의 예방 또는 완화
|
CA3195799A1
(en)
|
2020-11-11 |
2022-05-19 |
Stephen R. Martin |
Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
|
US20240033358A1
(en)
|
2020-11-13 |
2024-02-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
AU2021380659A1
(en)
|
2020-11-13 |
2023-06-01 |
Kenjockety Biotechnology, Inc. |
Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
AU2021376837A1
(en)
|
2020-11-16 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
US20240002521A1
(en)
|
2020-11-20 |
2024-01-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd25 antibodies
|
WO2022106665A1
(en)
|
2020-11-20 |
2022-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd25 antibodies
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
PE20232045A1
(es)
|
2020-12-04 |
2023-12-27 |
Hoffmann La Roche |
Polipeptidos de interleucina-2 mutante dependientes del ph
|
US20240016936A1
(en)
|
2020-12-04 |
2024-01-18 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
GB202019522D0
(en)
|
2020-12-10 |
2021-01-27 |
Oblique Therapeutics Ab |
Epitopes and antibodies
|
JP2024501452A
(ja)
|
2020-12-11 |
2024-01-12 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Braf阻害剤及び/またはmek阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
|
WO2022132923A1
(en)
|
2020-12-16 |
2022-06-23 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
JP2024500403A
(ja)
|
2020-12-17 |
2024-01-09 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球によるがんの治療
|
AU2021399841A1
(en)
|
2020-12-17 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022147092A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
EP4271998A1
(en)
|
2020-12-30 |
2023-11-08 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4271791A2
(en)
|
2020-12-31 |
2023-11-08 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
JP2024503826A
(ja)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1-lag3二重特異性抗体及びcd20 t細胞二重特異性抗体を用いる併用療法
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
EP4281484A1
(en)
|
2021-01-22 |
2023-11-29 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
JP2024504875A
(ja)
|
2021-02-01 |
2024-02-01 |
▲い▼尊生物医薬(浙江)有限公司 |
標的タンパク質分解システムおよびその応用
|
WO2022167460A1
(en)
|
2021-02-02 |
2022-08-11 |
Numab Therapeutics AG |
Multispecific antibodies having specificity for ror1 and cd3
|
EP4291580A1
(en)
|
2021-02-11 |
2023-12-20 |
Nectin Therapeutics Ltd. |
Antibodies against cd112r and uses thereof
|
EP4294834A2
(en)
|
2021-02-19 |
2023-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single domain antibodies that neutralize sars-cov-2
|
WO2022178253A1
(en)
|
2021-02-19 |
2022-08-25 |
IsoPlexis Corporation |
Methods and devices for spatially resolved analysis of proteomic and genetic information
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
EP4301776A1
(en)
|
2021-03-04 |
2024-01-10 |
Centre National de la Recherche Scientifique (CNRS) |
Use of a periostin antibody for treating inflammation, fibrosis and lung diseases
|
TW202300014A
(zh)
|
2021-03-05 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
腫瘤儲存及細胞培養組成物
|
IL305758A
(en)
|
2021-03-10 |
2023-11-01 |
Immunowake Inc |
Immunomodulatory compounds and their uses
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308118A1
(en)
|
2021-03-17 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating melanoma
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
EP4308691A1
(en)
|
2021-03-19 |
2024-01-24 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
EP4313317A1
(en)
|
2021-03-23 |
2024-02-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
TW202305118A
(zh)
|
2021-03-23 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
KR20230160366A
(ko)
|
2021-03-23 |
2023-11-23 |
피어이스 파마슈티컬즈 게엠베하 |
암 치료를 위한 her2/4-1bb 이중특이적 융합 단백질
|
WO2022200478A1
(en)
|
2021-03-24 |
2022-09-29 |
Pieris Pharmaceuticals Gmbh |
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
|
JP2024512029A
(ja)
|
2021-03-25 |
2024-03-18 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
T細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
|
WO2022207521A1
(en)
|
2021-03-30 |
2022-10-06 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20230165917A
(ko)
|
2021-04-08 |
2023-12-05 |
피어이스 파마슈티컬즈 게엠베하 |
결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
CN117202897A
(zh)
|
2021-04-09 |
2023-12-08 |
基因泰克公司 |
使用raf抑制剂和pd-1轴抑制剂的组合疗法
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
IL307598A
(en)
|
2021-04-16 |
2023-12-01 |
Juno Therapeutics Inc |
T-cell therapy in patients who have had a previous stem cell transplant
|
WO2022219152A1
(en)
|
2021-04-16 |
2022-10-20 |
Oblique Therapeutics Ab |
Kras antibodies
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
EP4326871A1
(en)
|
2021-04-19 |
2024-02-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
EP4326761A1
(en)
|
2021-04-20 |
2024-02-28 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Nk細胞係合剤関連の有害作用の防止または軽減
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2022273303A1
(en)
|
2021-05-14 |
2023-11-02 |
Genentech, Inc. |
Agonists of trem2
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CA3216320A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN115368473A
(zh)
|
2021-05-19 |
2022-11-22 |
上海诗健生物科技有限公司 |
一种特异性识别baff-r的嵌合抗原受体分子及其应用
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
WO2022251446A1
(en)
|
2021-05-28 |
2022-12-01 |
Alexion Pharmaceuticals, Inc. |
Methods for detecting cm-tma biomarkers
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
KR20240019109A
(ko)
|
2021-06-09 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
AU2021451307A1
(en)
|
2021-06-16 |
2024-02-01 |
Shanghai Sinobay Biotechnology Co., Ltd. |
Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
CN117545776A
(zh)
|
2021-06-22 |
2024-02-09 |
默克专利股份公司 |
基于vhh的nkp30粘结剂
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
CA3220353A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
TW202317190A
(zh)
|
2021-06-29 |
2023-05-01 |
美商思進公司 |
以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
KR20240029062A
(ko)
|
2021-07-02 |
2024-03-05 |
메르크 파텐트 게엠베하 |
항-protac 항체 및 복합체
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
WO2023283611A1
(en)
|
2021-07-08 |
2023-01-12 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing tnfr2 and uses thereof
|
WO2023285362A1
(en)
|
2021-07-12 |
2023-01-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of il-36 inhibitors for the treatment of netherton syndrome
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
WO2023287707A1
(en)
|
2021-07-15 |
2023-01-19 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
AU2022317820A1
(en)
|
2021-07-28 |
2023-12-14 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
WO2023006975A2
(en)
|
2021-07-30 |
2023-02-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric proteins and methods of immunotherapy
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
WO2023028186A1
(en)
|
2021-08-27 |
2023-03-02 |
Abbott Laboratories |
Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
AU2022339759A1
(en)
|
2021-08-31 |
2024-03-07 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023039488A1
(en)
|
2021-09-09 |
2023-03-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
CA3231944A1
(en)
|
2021-09-16 |
2023-03-23 |
Carole GUILLONNEAU |
Anti-human cd45rc binding domains and uses thereof
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
WO2023062050A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023072958A1
(en)
|
2021-10-25 |
2023-05-04 |
Fabmid |
Methods for circularizing linear double stranded nucleic acids and the products thereof
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
TW202325742A
(zh)
|
2021-11-01 |
2023-07-01 |
瑞士商赫孚孟拉羅股份公司 |
使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023083895A1
(en)
|
2021-11-10 |
2023-05-19 |
F. Hoffmann-La Roche Ag |
Hydrophilic azadibenzocyclooctyne derivatives and metal-free click reactions with these hydrophilic azadibenzocyclooctyne derivatives
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
EP4180518A1
(en)
|
2021-11-12 |
2023-05-17 |
Istituto Europeo di Oncologia S.r.l. |
T cells and uses thereof
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
TW202334203A
(zh)
|
2021-11-19 |
2023-09-01 |
德商皮里斯製藥有限公司 |
新穎的ox40及pd-l1特異性融合蛋白
|
TW202330623A
(zh)
|
2021-12-08 |
2023-08-01 |
美商英塞特公司 |
抗突變鈣網伴護蛋(calr))抗體及其用途
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023114658A1
(en)
|
2021-12-13 |
2023-06-22 |
Kenjockety Biotechnology, Inc. |
Anti-abcb1 antibodies
|
TW202339797A
(zh)
|
2021-12-14 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
使用hla-a2mage-a4xcd3雙特異性抗體及4-1bb(cd137)促效劑治療癌症
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
WO2023114884A2
(en)
|
2021-12-15 |
2023-06-22 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023118497A1
(en)
|
2021-12-22 |
2023-06-29 |
Pieris Pharmaceuticals Gmbh |
Novel il-18 variants
|
WO2023122796A1
(en)
|
2021-12-23 |
2023-06-29 |
The Broad Institute, Inc. |
Parallel antibody engineering compositions and methods
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023147329A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation and methods thereof
|
WO2023147328A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023148707A1
(en)
|
2022-02-07 |
2023-08-10 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
EP4223302A1
(en)
|
2022-02-08 |
2023-08-09 |
Universität Heidelberg |
Oncolytic measles virus encoding a bike and methods of use thereof in treating cancer
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023156683A1
(en)
|
2022-02-21 |
2023-08-24 |
Acticor Biotech |
Treatment of cardiovascular diseases using anti-human gpvi antibodies
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
GB202202569D0
(en)
|
2022-02-24 |
2022-04-13 |
Amlo Biosciences Ltd |
Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
|
WO2023170207A1
(en)
|
2022-03-09 |
2023-09-14 |
Alderaan Biotechnology |
Anti-cd160 transmembrane isoform antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023180523A1
(en)
|
2022-03-24 |
2023-09-28 |
Pieris Pharmaceuticals Gmbh |
Process for purifying fusion proteins
|
TW202402790A
(zh)
|
2022-03-25 |
2024-01-16 |
英商梅迪繆思有限公司 |
減少呼吸系統感染之方法
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023215719A1
(en)
|
2022-05-02 |
2023-11-09 |
Arcus Biosciences, Inc. |
Anti-tigit antibodies and uses of the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2023237431A1
(en)
|
2022-06-07 |
2023-12-14 |
Esocap Ag |
Drug delivery system comprising an agent effective in the treatment or prevention of an esophageal disease for the application to esophageal mucous membranes
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237661A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
Use of endothelin receptor type b agonists for the treatment of aortic valve stenosis
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024003380A1
(en)
|
2022-06-30 |
2024-01-04 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013234A1
(en)
|
2022-07-13 |
2024-01-18 |
Institut National de la Santé et de la Recherche Médicale |
Methods for diagnosis, prognosis, stratification and treating of myocarditis
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024056861A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for stimulating nk cells and use thereof
|
WO2024059692A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Hbv diagnostic, prognostic, and therapeutic methods and products
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|